All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Reperfusion injury occurs upon restoration of blood flow after a prolonged period of ischemia. It has major clinical significance because reperfusion is essential to restore heart function yet may precipitate further irreversible injury, and thus limit the extent of myocardial salvage. A key player in ischemia-reperfusion (I/R) injury is the opening of a non-selective, high conductance channel in the inner mitochondrial membrane (IMM) known as the mitochondrial permeability transition pore (mPTP) \[[@pone.0234653.ref001]\] whose exact molecular identity remains uncertain \[[@pone.0234653.ref002]--[@pone.0234653.ref005]\]. It has been widely accepted that the major triggers for mPTP opening during reperfusion are elevated \[Ca^2+^\]~m~ and reactive oxygen species (ROS) \[[@pone.0234653.ref001]\]. It has been further proposed that ROS are generated early in reperfusion by reverse electron flow through Complex I of the respiratory chain during oxidation of succinate that accumulates in ischemia \[[@pone.0234653.ref006]\]. However, our own real-time surface fluorescent measurements of ROS during reperfusion do not support this hypothesis \[[@pone.0234653.ref007]\]. Indeed, ischemic preconditioning (IPC), in which hearts are exposed to several brief periods of ischemia and reperfusion prior the prolonged ischemic episode, is strongly cardioprotective but is not accompanied by a reduction in succinate accumulation \[[@pone.0234653.ref007], [@pone.0234653.ref008]\]. Furthermore, Cyclosporine A (CsA), a specific inhibitor of the mPTP that acts by binding to an established regulatory component of the pore (cyclophilin D), has failed to show reduction in mortality and adverse effects of I/R in clinical settings \[[@pone.0234653.ref009]\] despite its cardioprotection in many animal models. These observations raise the question whether simple inhibition of the mPTP is sufficient to prevent I/R injury and whether targeting events upstream of mPTP opening might be more effective.

In this respect, we have previously shown that although the mPTP remains closed during ischemia \[[@pone.0234653.ref010]\], events occurring during this period sensitize mitochondria to mPTP opening at reperfusion \[[@pone.0234653.ref011]\]. Thus, mitochondria isolated from ischemic hearts are much more sensitive to mPTP opening than those from control hearts. However, IPC or pharmacological preconditioning attenuates this sensitization \[[@pone.0234653.ref011], [@pone.0234653.ref012]\] and thus leads to less mPTP opening on reperfusion and consequently less injury. More recently \[[@pone.0234653.ref007]\] we showed that IPC did not attenuate the elevated \[Ca^2+^\]~m~ at the end of ischemia or ROS production in the first 90 s of reperfusion yet mPTP opening after 1 min and subsequent ROS production was attenuated. This confirms that mitochondria experience an effect during ischemia that determines mPTP opening and thus the extent of injury on reperfusion. In this regard, ischemia is associated with a decrease in the amount of hexokinase 2 (HK2) bound to mitochondria which is caused by accumulation of glucose-6-phosphate (G6P) and a drop in cytosolic pH that occurs as a result of enhanced glycolysis during this phase \[[@pone.0234653.ref013]\]. IPC attenuates these metabolic changes and prevents the dissociation of mitochondrial-bound HK2 (mt-HK2), suggesting this may be an important component of the IPC mechanism. In this context it should be noted that mitochondria-bound HK2 has also been implicated in the resistance of tumour cell mitochondria to mPTP opening \[[@pone.0234653.ref014]--[@pone.0234653.ref017]\]. Furthermore, extensive earlier studies from our laboratory \[[@pone.0234653.ref013], [@pone.0234653.ref018], [@pone.0234653.ref019]\] and those of others \[[@pone.0234653.ref020]--[@pone.0234653.ref023]\] have demonstrated a strong correlation between dissociation of mt-HK2 during ischemia and cytochrome c release and infarct size at reperfusion. In this regard, cytochrome c loss decreases superoxide scavenging and promotes ROS production \[[@pone.0234653.ref019]\] which are known inducers of the mPTP \[[@pone.0234653.ref001]\]. By contrast, IPC does not reduce the accumulation of succinate, a proposed source of ROS, during ischemia or the rate of its subsequent decline on reperfusion \[[@pone.0234653.ref007], [@pone.0234653.ref008]\] but does prevent HK2 loss from mitochondria during ischemia \[[@pone.0234653.ref013]\]. Yet, despite the numerous reports about hexokinase(s) on cell survival, either in the context of cardiovascular injury and/or cancer, none of these papers provide definite evidence of whether or how HK2 can modulate mPTP opening directly. Rather they have primarily investigated upstream events leading to mt-HK2 release, such as the potential roles of Akt and GSK3beta, reporting mt-HK2 dissociation as the last event in a cascade that leads to mPTP opening. They do not provide evidence that HK2 directly regulates mPTP opening.

Previous data from our laboratory have offered some insights into the mechanism by which mt-HK2 might interact with the mPTP. We observed that rates of phosphocreatine (PCr) regeneration following prolonged ischemia are depressed \[[@pone.0234653.ref013]\], suggesting a disruption of the PCr-dependent energy shuttling system that involves interactions between the outer and inner mitochondrial membranes (OMM and IMM). Another hetero-protein complex found at points of juxtaposition between OMM and IMM comprises the adenine nucleotide translocase (ANT), the voltage-dependent anion channel (VDAC) and, importantly for the present study, HK \[[@pone.0234653.ref024]\]. Interestingly, we \[[@pone.0234653.ref025]\] and others \[[@pone.0234653.ref026]\] have reported that modulation of such contact sites in isolated mitochondria is associated with cytochrome c release and increased sensitivity to mPTP opening. These data suggest a plausible role for OMM and IMM interactions in linking extra-mitochondrial events that occur during ischemia to sensitization of mPTP opening during I/R.

The primary aim of this study was to establish whether the deleterious effects of ischemia on mitochondria *in vitro* can be mimicked purely by displacing mt-HK2. Using a brief incubation with G6P at pH 6.3 during mitochondrial isolation, we have dissociated HK2 from mitochondria isolated from pre-ischemic and end-ischemic control and IPC hearts and subsequently measured OMM permeabilization (OMMP), the sensitivity of the mPTP and changes in OMM and IMM morphology. Our rationale is that, if prevention of HK2 dissociation from mitochondria is directly responsible for the attenuation of changes to mitochondria function at the end of ischemia, then its removal from IPC end-ischemic mitochondria should change these parameters back to those of non-preconditioned end-ischemic mitochondria. However, our data reveal that HK2 dissociation *in vitro* does not replicate ischemia-induced effects on these parameters which leads us to conclude that release of mitochondrial-bound HK2 *in vivo* must affect mitochondrial morphology and function indirectly. We present preliminary evidence that this may be achieved by modulating the binding of the mitochondrial fission proteins Drp1 and mitochondrial-associated dynamin 2 (Dyn2).

Material and methods {#sec002}
====================

Animals {#sec003}
-------

Male Wistar rats, RccHan:WIST (225--275 g), were purchased from Harlan (Oxfordshire, UK), acclimatized for 5--7 days prior to the initiation of experiments and maintained in the local animal house facility (Biomedical Sciences Building, University of Bristol, Bristol, UK). Animals were group-housed in grilled top type IV cages with corncob grit bedding and environmental enrichment (irradiated tissue paper and cardboard for nest building and shelter) as means of improving animal welfare. Cages were maintained under controlled environmental requirements (22 °C, 45--65% humidity, 15--20 air changes/hour, 12 h artificial light/dark cycle, noise level \< 55 dB); and, free access to rodent food (EURodent Diet 22%, 5LF5, Labdiet, St. Louis, MO, US) and water ad libitum. Animals were euthanized by concussion followed by cervical dislocation, and hearts were immediately extracted from the body and quickly immersed in ice-cold Krebs--Henseleit buffer.

Animal handling was performed in accordance with the European Convention for the Protection of Vertebrate Animals used for Experimental and Other Scientific Purposes (CETS no.123), the UK Animals (Scientific Procedures) Act 1986 amendment regulations 2012 and was approved by the appropriate University of Bristol ethics committee (UB/09/012). G.C.P. is credited by the European Federation for Laboratory Animal Research (FELASA) category C for animal experimentation (accreditation no. 020/08).

Heart perfusion {#sec004}
---------------

Langendorff retrograde heart perfusion was performed as previously described \[[@pone.0234653.ref018]\] using constant flow (12 mL/min) with Krebs--Henseleit buffer (NaCl 118 mM, NaHCO~3~ 25 mM, KCl 4.8 mM, KH~2~PO~4~ 1.2 mM, MgSO~4~ 1.2 mM, glucose 11 mM and CaCl~2~ 1.2 mM) gassed with 95% O~2~ / 5% CO~2~ at 37 °C. After cannulation, hearts were perfused for 35 min followed by 30 min global normothermic ischemia (index ischemia), induced by halting perfusion and immersing the heart in perfusion buffer at 37 °C. Ischemic pre-conditioning (IPC) was induced after 20 min perfusion by three cycles of 2 min ischemia plus 3 min reperfusion before entering index ischemia as described above. Hemodynamic monitoring was achieved by inserting a latex balloon connected to a pressure transducer into the left ventricle. Data acquisition and analysis were performed using PowerLab/LabChart (AdInstruments, Oxford, UK). A summary of the hemodynamic data is presented in the supplemental [S1](#pone.0234653.s008){ref-type="supplementary-material"}, [S2](#pone.0234653.s009){ref-type="supplementary-material"} and [S3](#pone.0234653.s010){ref-type="supplementary-material"} Tables.

For hearts used to assess the content of mitochondrial dynamic proteins (ie., Drp1, Mff and Dyn2) the standard perfusion protocol was changed as following: control perfusion (pre-ischemia), 45 min perfusion; end-ischemia, 15 min stabilisation followed by 30 min global normothermic ischemia; IPC, 15 min stabilisation followed by 3 cycles of 2 min bursts of ischemia separated by 3 min perfusion, then 30 min global normothermic ischemia.

Assessment of infarct size {#sec005}
--------------------------

For assessment of infarct size hearts were reperfused for 120 min after ischemia before perfusing for 2 min at 10 mL/min with a 1% (w/v) TTC solution. Hearts were then detached from the cannula and incubated for an additional 5 min at 37 °C before being sliced perpendicular to the longitudinal axis into 6 slices. The slices were then fixed in 4% (w/v) formalin solution overnight at 4°C. Both sides of each slice were imaged on a standard office scanner and acquisition settings were maintained for all analysed hearts. The surfaces of the necrotic and area at risk of each side for each slice were determined by planimetry using a color threshold in ImageJ (NIH, Bethesda, MD, USA). Because global ischemia was used, infarct size was expressed as a percentage of the total cross-sectional area of the heart. A summary of the data obtained is shown in the supplemental [S3 Table](#pone.0234653.s010){ref-type="supplementary-material"}.

Mitochondria isolation {#sec006}
----------------------

Hearts were removed from the cannula either before entering ischemia (pre-ischemia) or at the end of ischemia, and immediately immersed in ice-cold isolation buffer (sucrose 300 mM, EGTA 2 mM, and Tris-HCl 10 mM, pH 7.3 at 4 °C). Mitochondria were isolated through differential centrifugation as described previously \[[@pone.0234653.ref018]\], with slight modifications. All steps were performed at 4 °C. Briefly, hearts were finely chopped with a razor blade on a glass petri dish and incubated at 4 °C for 4.5 min with stirring in a small beaker with 6 mL of isolation buffer supplemented with 1.12 U/mL of protease (EC 3.4.21.62, Subtilisin A) from Bacillus licheniformis (aqueous propylene glycol solution from Sigma-Aldrich, Dorset, UK). The suspension was then filtered through a nylon mesh (100 μm) and washed with 7 volumes of isolation buffer before transfer into a glass Potter homogenizer. Homogenization was carried out in 25 mL of isolation buffer supplemented with 0.5% defatted BSA for about 2 min using a motorized Teflon pestle. The homogenate was centrifuged at 7,500 g for 7 min, and the resulting pellet was re-suspended in 25 mL of isolation buffer with BSA and subjected to additional homogenization as described earlier. The suspension was then centrifuged at 700 g for 10 min and the resultant supernatant saved while the pellet was re-suspended in 25 mL of isolation buffer, homogenized as previously described in isolation buffer and centrifuged at 700 g for 10 min. This second supernatant was mixed with the first and centrifuged at 7,000 g for 10 min to yield a crude mitochondrial pellet. Half of each pellet was re-suspended in 10 mL of normal isolation buffer and half in isolation buffer containing 10 mM G6P at pH 6.3; both were then centrifuged at 7,000 g for 10 min. The resulting pellets were re-suspended in isolation buffer containing 25% (w/v) Percoll (pH 7.2 at 4 °C) and centrifuged at 17,000 g for 10 min. The mitochondrial pellets were re-suspended in isolation buffer and centrifuged again at 7,000 g for 10 min. The final purified mitochondrial pellets were re-suspended in a small volume of isolation buffer, and the protein concentration determined by the Biuret method using BSA as a standard. Mitochondria were kept on ice at a final concentration of 20--25 mg/mL and used within 4 hours. The protocol for mitochondrial preparation and treatment is summarized in [S1 Fig](#pone.0234653.s001){ref-type="supplementary-material"}.

For hearts used to assess the content of mitochondrial dynamic proteins (ie., Drp1, Mff and Dyn2) a modification of the polytron method \[[@pone.0234653.ref018]\] was used instead. Briefly, left ventricle was immersed in 6 mL ice-cold isolation buffer (300 mM sucrose, 3 mM EGTA, 10 mM Tris-HCl, pH 7.1) supplemented with 20 mM NEM, 1x complete protease inhibitors (Roche) and 1x phosphatase inhibitors. Tissue was rapidly chopped into fine pieces before homogenization using a Polytron tissue disruptor (Kinematica) at 10,000 rpm with 2 bursts of 5 seconds followed by 1 burst of 10 seconds. Tissue homogenate was diluted to 20 mL total volume with isolation buffer supplemented with 1x complete protease inhibitors and further homogenized by hand for 2 min using a glass Potter homogenizer and Teflon pestle. A small volume of homogenate was stored at -80 °C as whole homogenate. The homogenate was centrifuged at 7,500 g for 7 min. The pellet was rinsed twice with 5 mL isolation buffer, resuspended in 20 mL isolation buffer and further hand-homogenized for 2 min. The homogenate was then centrifuged at 600 g for 10 min and the supernatant was centrifuged at 7,000 g for 10 min to yield a crude mitochondrial pellet, which was resuspended in isolation buffer and stored at -80 °C. All fractions were assayed for protein concentration using a standard BCA assay protocol prior to use for Western blotting.

Mitochondrial respiration {#sec007}
-------------------------

Oxygen consumption by isolated mitochondria was monitored polarographically with an Oxygraph-2k (Oroboros Instruments, Innsbruck, Austria) at 37 °C in a 2 mL chamber with standard respiration medium (KCl 125 mM, MOPS 20 mM, Tris 10 mM, EGTA 10 μM, KH~2~PO~4~ 2.5 mM, and MgCl~2~ 2.5 mM, adjusted to pH 7.3 at room temperature with KOH). The respiratory substrates, 5 mM L-glutamate, 2 mM L-malate and 5 mM succinate, were added to the reaction chamber and allowed to equilibrate before addition of 0.25 mg/mL of mitochondria and closing of the chamber. After a stable state 2 respiration was achieved, ADP in excess (1.5 mM) was added, followed by 10 μM of cytochrome c to assess the permeability of the mitochondrial outer membrane to cytochrome c (indicated by the extent to which the rate of respiration was enhanced). Experiments were performed in duplicate using both Oxygraph-2k chambers. Respiration rates were calculated as the average value over a 45 s window in DatLab 5 (Oroboros Instruments) and are expressed in nmol O~2~ / min /mg protein.

Mitochondrial permeability transition {#sec008}
-------------------------------------

Opening of the mPTP in isolated mitochondrial fractions was assessed both in energized and de-energized conditions. In **energized conditions**, extramitochondrial \[Ca^2+^\] was assayed by monitoring Fura-FF (Life Technologies, Paisley, UK) fluorescence in a multi-wavelength fluorimeter (Cairn Instruments, Kent, UK). Excitation filters, 340/20 nm and 380/20 nm, were contained in a spinning wheel rotating continuously at 32 Hz. Emission fluorescence was detected at 90° with a photomultiplier using a 520 nm bandpass filter. Mitochondria (0.25 mg/mL) were incubated at 30 °C within a stirred cuvette containing 2 mL assay buffer (KCl 125 mM, MOPS 20 mM, TRIS 10 mM, EGTA 20 μM, KH~2~PO~4~ 2 mM and Fura-FF 1 μM, pH 7.2 at 30 °C) supplemented with respiratory substrates (5 mM L-glutamate, 2 mM L-malate and 5 mM succinate). Additions of 20 μM free \[Ca^2+^\] were made every 2 min through an injection port (first pulse of 50 μM \[Ca^2+^\]~total~). Calcium-loading capacity was calculated as the sum of number of Ca^2+^ pulses until mPTP opening, defined by an incomplete plateau before the next Ca^2+^ addition.

Under **de-energized conditions**, mPTP was determined by following the decrease in light scattering at 520 nm (*A*~520~) using a split-beam spectrophotometer with computerized data acquisition \[[@pone.0234653.ref027]\]. Mitochondria (0.25 mg/mL) were incubated at 25 °C within a stirred cuvette containing 2 mL assay buffer (KCl 125 mM, MOPS 20 mM, TRIS 10 mM, nitrilotriacetic acid (NTA) 2 mM, KH~2~PO~4~ 2.5 mM, rotenone 1 μM, antimycin A 1 μM and A23187 2 μM, pH 7.2 at 25 °C). A23187 was present to ensure complete equilibration of Ca^2+^ across the mitochondrial inner membrane under de-energized conditions \[[@pone.0234653.ref028]\]. Addition of a single pulse of 83.5 μM \[Ca^2+^\]~free~ (1mM \[Ca^2+^\]~total~) was made through an injection port after an 80 s baseline. Variation in the initial A~520~ (\~0.5) was less than 10%. The initial rate of decrease in *A*~520~ was calculated as the minimum of the first derivative of the *A*~520~ time course.

In both cases, values of free \[Ca^2+^\] were calculated by a ligand-binding program (METLIG), as previously described \[[@pone.0234653.ref029]\]. Whenever indicated, 0.2 μM of cyclosporine A (CsA) was added in order to desensitize mPTP opening \[[@pone.0234653.ref030]\].

Measurement of inner mitochondrial morphology {#sec009}
---------------------------------------------

Extensive work from the laboratories of Sirak \[[@pone.0234653.ref031]\] and Klingenberg \[[@pone.0234653.ref032]\] demonstrated that ANT ligands modulate the light scattering (LS) of mitochondrial suspension as the ANT switches between its '*c'* and '*m'* conformations. Previous work from this laboratory has shown that these LS changes are independent of changes in mitochondrial matrix volume and may therefore provide an alternative means by which to monitor cristae morphology \[[@pone.0234653.ref033]\]. Here we use this approach in mitochondria isolated from the perfused heart either before ischemia of after 30 min ischemia with or without IPC.

### Light scattering measurements {#sec010}

Light scattering (LS) was monitored at 520 nm (*A*~520~) in a split-beam spectrophotometer with computerized data acquisition (1 data point per sec). Mitochondria (0.375 mg/mL) were suspended in assay buffer (KCl 125 mM, MOPS 20 mM, TRIS 10 mM, EGTA 0.5 mM, pH 7.2 at 25 °C) supplemented with respiratory substrates (5 mM L-glutamate, 2 mM L-malate and 5 mM succinate) and oligomycin (1 μM) at 25 °C. Equal volumes (2 mL) were used in sample and reference cuvettes and additions (463.5 μM \[Ca^2+^\]~total~ equivalent to 1 μM \[Ca^2+^\]~free~, 0.2 mM ADP and 5 μM CAT) were made to the sample cuvette as required through an injection port followed by stirring for 5 s. Variation in the initial *A*~520~ (\~0.5) was less than 10%. The magnitude of the changes in *A*~520~ was calculated after signal stabilization and was expressed relative to the *A*~520~ prior to effector addition (or baseline for the first addition). The rate of change in *A*~520~ was calculated as the maximum (negative or positive) of the first derivative of the absorbance traces. Free \[Ca^2+^\] was calculated by a ligand-binding program (METLIG), as previously described \[[@pone.0234653.ref029]\].

### Transmission electron microscopy {#sec011}

Assessment of mitochondrial ultrastructure was performed by TEM. Mitochondria were incubated as for LS measurements above, but protein concentration was scaled up to 0.75 mg/mL. When *A*~520~ reached a constant signal, the mitochondrial suspension was fixed by addition of glutaraldehyde (3% (w/v) final) and incubated for 20 min at room temperature. Mitochondria were then sedimented by centrifugation at 3,000 g for 1 min and re-suspended in 0.1 M cacodylate for 10 min. The procedure was repeated twice before post-fixation with 1% (w/v) osmium tetraoxide in cacodylate buffer for 20 min at room temperature. Samples were washed 3 times with cacodylate buffer followed by standard embedding in Epon 812. Sections (60nm) were contrasted with Ur-acetate and Pb-citrate and analyzed on a FEI Technai12 TEM.

Mitochondria were classified and counted accordingly to their inner membrane morphology as illustrated in [Fig 6](#pone.0234653.g006){ref-type="fig"}: *Type I*, mitochondria present evenly spaced cristae with regular width; *Type II*, mitochondria present irregular cristae width but cristae are still thread-like, traversing from OMM to OMM. Spacing between cristae becomes irregular. *Type III*, mitochondria show a *Type II* configuration but at least two vesicular-like cristae are present. This reflects a combination between *Type II* and *Type IV* configurations. *Type IV*, mitochondria present rounded, nearly vesicular cristae without cristae traversing. Counting was performed in duplicate using non-overlapping micrographs and by two independent operators blind to the treatment whose scoring (agreeing within 10%) was averaged.

For morphometric analysis each mitochondrion was manually segmented and the respective mask used to measure its *area*, *perimeter*, *circularity* (4π.\[area/perimeter\^2\]) and *aspect ratio* (major axis/minor axis). For segmentation of all mitochondrial membranes a band pass filter was applied to the original EM picture in order to filter large structures down to 40 pixels and small structures up 10 pixels. Then, an Otsu threshold filtering was applied to the processed image and the resulting mask used to analyze particles with an average size bigger than 5000 pixels ([S7 Fig](#pone.0234653.s007){ref-type="supplementary-material"}). A summary of the data obtained is shown in the supplemental [S4 Table](#pone.0234653.s011){ref-type="supplementary-material"}. Image processing was performed in FIJI (ImageJ v1.51d).

Western blot {#sec012}
------------

Isolated mitochondrial fractions were diluted to 2.5 mg/mL in sample buffer (Tris 25 mM, glycerol 6% (w/v), SDS 5% (w/v), EDTA 1 mM and bromophenol blue 0.005% (w/v)) supplemented with 5% (w/v) β-mercaptoethanol and heated at 95 °C for 5 min. Proteins were separated in 5% (HK2 and HK1) or in 12% (ANT, Drp1, Mff, Dyn2) polyacrylamide casted gels by SDS-PAGE using 20 μg per lane. Gels were then subjected to Western blotting with the required primary antibody (HK2 (C64G5) rabbit monoclonal dilution 1:1,000, cat. \#2867, Cell Signalling, Hertfordshire, UK; HK1 mouse monoclonal 5G9 dilution 1:1,000, cat. \# WH0003098M1, Chemicon Millipore, Watford, UK; ANT---raised in-house against the C terminus of rat ANT \[[@pone.0234653.ref034]\], dilution 1:1,000; Drp1 mouse monoclonal dilution 1:1,000, cat. \#611112, BD Biosciences, Wokingham; Dyn2 mouse monoclonal dilution 1:1,1000, cat. \# SAB4200661, Sigma-Aldrich; Mff mouse monoclonal C11 dilution 1:2,000, cat. \#sc-398731, Santa-Cruz Biotechnology, USA; GAPDH mouse monoclonal 6C5 dilution 1:20,000, cat. \#ab8245, AbCam, Cambridge, UK; VDAC-1/2/3 rabbit polyclonal FL-283 dilution 1:1,1000, cat. \#sc-9878, Santa-Cruz Biotechnology) and blots were developed using the required Ig HRP (horseradish peroxidase) secondary antibody, with ECL/ECL+ detection (Amersham Biosciences, Buckinghamshire, UK). Appropriate exposures of the film were used to ensure that band intensities were within the linear range. Quantification of blots was performed using an Alpha Inotech ChemiImager 4400 (Alpha Innotech Corp., San Leandro, CA, USA) to image the blot and analysis of band intensity with Quantity One (Bio-Rad Laboratories, Hercules, CA, USA). For densitometry, a rectangle with the maximum size similar to the band of greatest length present in the blot was considered as the region of interest and was used through the entire blot. Total band density, defined as the sum of all pixels intensity corrected for the local mean background was used. Each blot contained samples of (± low pH + G6P) pre-ischemic, end-ischemic and IPC end-ischemia mitochondria to allow direct comparisons between groups using the same film exposure. In order to normalize band intensities, parallel blots were performed on the same samples using antibodies against the ANT.

Enzyme activities {#sec013}
-----------------

Isolated mitochondrial fractions were disrupted using hypotonic shock induced by dilution to 2 mg/mL in phosphate buffer (KH~2~PO~4~ 33 mM pH 7.2 at room temperature) and incubation for 15 min on ice followed by one cycle of freeze-thaw.

Total **hexokinase activity** was evaluated in 1 mL of assay buffer (pH 7.4 at room temperature) containing Tris-HCl 100 mM, NADP^+^ 0.4 mM, MgCl~2~ 10 mM, ATP 5 mM, Triton X-100 0.3% (v/v), G6P dehydrogenase 0.5 U/mL and 60 μg of protein. The reaction was carried out at 37 °C in an Evolution 300 UV-Vis Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA) and started after a 2 min baseline by addition of glucose (1 mM final). Hexokinase activity was calculated from the rate of NADPH production over the linear part of the assay (8 min) using an extinction coefficient of 6.22 mM^-1^.cm^-1^ \[[@pone.0234653.ref035]\]. Values were then normalized to citrate synthase activity and expressed as nmol NADPH/min/citrate synthase unit.

**Citrate synthase** activity was evaluated in 1 mL of assay buffer (pH 7.4 at room temperature) containing Tris-HCl 50 mM, Triton X-100 0.3% (v/v), and 5,5′-dithiobis-2-nitrobenzoic acid (DTNB) 150 μM, acetyl-coenzyme A 0.3 mM and 10 μg of protein. The reaction was carried at 37 °C and started after a 2 min baseline by addition of oxaloacetic acid (500 μM final). Citrate synthase activity was expressed in μmol /min/mg protein.

Statistical analysis {#sec014}
--------------------

All data were assessed for normality using the Kolmogorov-Smirnov test with Dallal-Wilkinson- Lillie for correction. Overall, analyzed data were normally distributed. Since group sample sizes are equal and the parametric statistical tests applied are robust for moderate deviations from homoscedasticity, parametric tests were always applied \[[@pone.0234653.ref036]\]. Statistical significance between groups was determined using matched-pairs (± G6P low pH) two-way ANOVA with interaction; *perfusion protocol* and *low pH + G6P* were the factors in use. Two types of comparisons were performed: 1) main *perfusion protocol* effect against *end-ischemia* group; 2) *low pH + G6P* effect individually analyzed for each perfusion group. In both cases, p values were adjusted for multiple comparisons through Holm-Šídák pos-hoc test and differences were considered significant at 5% level.

Frequency distributions of morphometric data from EM were expressed relatively to the total number of measured objects (mitochondria; [S4 Table](#pone.0234653.s011){ref-type="supplementary-material"}), with bin range and width defined automatically by the software (Graph Pad Prism). Afterwards, a Gaussian distribution was fitted to the data and independent fits between groups were compared to a global fit sharing the same *mean* by the extra sum-of-squares F test. The resulting p value was adjusted for multiple comparisons through Holm-Šídák pos-hoc test and differences were considered significant at 5% level.

Statistical analyses were performed using Graph Pad Prism version 6.01 (GraphPad Software, Inc., San Diego, CA, USA).

Results {#sec015}
=======

Hemodynamic parameters during ischemia and IPC {#sec016}
----------------------------------------------

Under the perfusion conditions used in the present studies, there were no differences in hemodynamic data between 'pre-ischemia' and 'end-ischemia' groups prior to entering ischemia ([S1 Table](#pone.0234653.s008){ref-type="supplementary-material"}). Hearts subjected to 30 min global ischemia showed an onset of ischemic contracture at 11.9 ± 0.7 min ([S2 Table](#pone.0234653.s009){ref-type="supplementary-material"}) and developed an infarct area upon 2 h reperfusion of 24.7 ± 2.0% ([S3 Table](#pone.0234653.s010){ref-type="supplementary-material"}). As expected, IPC treatment lowered aortic pressure and rate pressure product at the end of the stabilization period ([S1 Table](#pone.0234653.s008){ref-type="supplementary-material"}) and reduced the time to ischemic contracture (7.8 ± 0.2 min) and infarct size (5.2 ± 0.7%) at reperfusion ([S2](#pone.0234653.s009){ref-type="supplementary-material"} and [S3](#pone.0234653.s010){ref-type="supplementary-material"} Tables, respectively).

*In vitro* dissociation of mitochondrial-bound HK2 {#sec017}
--------------------------------------------------

Previously we demonstrated that mitochondria-bound HK2 requires both an increase in G6P and a decrease in pH to be released from mitochondria *in situ* \[[@pone.0234653.ref018]\]. Thus, to promote HK2 dissociation *in vitro*, we modified the standard mitochondrial isolation protocol by including an extra washing step with either the standard isolation buffer (*normal*) or one supplemented with 10 mM G6P at pH 6.3 (*low pH + G6P*). It should be noted that the G6P and *low pH* are not present in the final wash and thus are not carried through into subsequent assays of mitochondrial function (see [S1 Fig](#pone.0234653.s001){ref-type="supplementary-material"}). We believe this protocol to be preferable to the use of synthetic peptides mimicking the HK2 binding peptide since these might be carried through into the assay and mimic the bound HK2 in its effects on the mPTP. Indeed, isolated cardiac mitochondria of mice overexpressing GFP fused to this peptide show successful dissociation of mt-HK2 but retention of the recombinant protein \[[@pone.0234653.ref037]\].

The western blot data of [Fig 1a](#pone.0234653.g001){ref-type="fig"} demonstrate that, as anticipated, our *low pH + G6P* protocol was effective in removing all bound HK2 from mitochondria isolated from control, ischemic and IPC ischemic hearts. These data also confirm our earlier observation that ischemia induces dissociation of mt-HK2 *in situ* which is prevented by IPC \[[@pone.0234653.ref018]\]. The fact that mt-HK2 from end-ischemic hearts can be further reduced *in vitro* indicates that the ischemic insult was not extreme, suggesting that further damage could have been attained to the heart. This agrees with our previous findings \[[@pone.0234653.ref013]\] where variations to the standard perfusion protocol led to different amounts of mt-HK2 being retained at end of ischemia, correlating with cardiac damage at reperfusion.

![Effects of ischemia and *low pH plus G6P* treatments on mitochondrial-bound HK2.\
Incubation of mitochondria during isolation with factors know to induce HK2 dissociation \[[@pone.0234653.ref018]\] completely removes HK2 from mitochondria: a---HK2 protein content (representative blots are shown on panel c and uncropped membranes on [S2b Fig](#pone.0234653.s002){ref-type="supplementary-material"}), b---Total HK activity. Data are presented as mean ± SEM of 6--8 independent experiments on different mitochondrial preparations. Differences between groups were evaluated by a matched pair (± G6P low pH) two-way ANOVA with interaction followed by Holm-Šídák pos-hoc test to correct for multiple comparisons. $\text{p}_{\text{interaction}}^{\text{HK2}\mspace{720mu}\text{content}} < 0.001$; $\text{p}_{\text{interaction}}^{\text{HK}\mspace{720mu}\text{activity}} = 0.011$; \*\*\*, p \< 0.001. Absolute values of citrate synthase (CS) activity (units per mg protein) were 2.30 ± 0.17, 2.59 ± 0.13, 2.69 ± 0.13 for pre-ischemia, end-ischemia and IPC end-ischemia, respectively. Corresponding values for low pH + G6P treated pre-ischemia, end-ischemia and IPC end-ischemia mitochondria were 2.32 ± 0.17, 2.38 ± 0.12 and 2.66 ± 0.18 respectively. c---representative blots for HK2 and HK1, as well as the ANT as loading control, of isolated mitochondrial fractions extracted from hearts perfused with different protocols (pre-ischemia, end-ischemia or IPC end-ischemia) ± *in vitro* HK2 dissociation protocol ('low pH plus G6P'); uncropped blots are shown on [S2d Fig](#pone.0234653.s002){ref-type="supplementary-material"}.](pone.0234653.g001){#pone.0234653.g001}

Further confirmation of the western blot data was provided by measurement of mitochondrial HK activity which was greatly reduced but not totally abolished by the protocol ([Fig 1b](#pone.0234653.g001){ref-type="fig"}). The remaining activity can be accounted for by the bound HK1 that was not dissociated by the treatment ([Fig 1c](#pone.0234653.g001){ref-type="fig"}), but which remains constant regardless of the perfusion protocol used as previously shown in *ex vivo* perfusion \[[@pone.0234653.ref013], [@pone.0234653.ref023]\]. It should be noted that low pH alone had no effect on total mt-HK activity ([S2 Fig](#pone.0234653.s002){ref-type="supplementary-material"}) or mt-HK2 content \[[@pone.0234653.ref018]\] in agreement with our previous data obtained in permeabilized cardiac fibers.

*In vitro* dissociation of HK2 has no effect on mitochondrial respiration or outer membrane permeabilization {#sec018}
------------------------------------------------------------------------------------------------------------

Next, we investigated the effects of mt-HK2 removal on mitochondrial respiration and OMMP as reflected by cytochrome c loss. Oxygen consumption was determined in the presence of both succinate that feeds electrons into Complex II and L-glutamate plus L-malate to generate NADH which feeds electrons into Complex I. These conditions most closely match the conditions *in vivo* \[[@pone.0234653.ref019]\]. Averaged traces (n = 8) of all analyzed groups are presented in [Fig 2a](#pone.0234653.g002){ref-type="fig"} and show that there is no significant difference between normal mitochondria and those depleted of HK2, regardless of the respiratory state (i.e. basal = state 2 and ADP-stimulated = state 3). Nevertheless, mitochondria from end-ischemic hearts exhibited an increase in state 2 respiration (31.7 ± 1.2 *vs*. 25.6 ± 1.6 nmol O~2~/min/mg of pre-ischemic, p = 0.004, n = 8) and depressed state 3 respiration ([Fig 2b](#pone.0234653.g002){ref-type="fig"}) as reported previously \[[@pone.0234653.ref019]\]. As expected, IPC treatment was able to prevent the latter, but state 2 rates remained slightly higher than pre-ischemic values (34.65 ±1.4 nmol O~2~/min/mg, p = 0.056 *vs*. end-ischemia, n = 8). In order to quantify OMMP we measured the stimulation of state 3 respiration induced by addition of exogenous cytochrome c. Dissociation of HK2 alone had no effect on this parameter ([Fig 2c](#pone.0234653.g002){ref-type="fig"}), but as we have previously reported \[[@pone.0234653.ref018]\], end-ischemia mitochondria showed higher OMMP that was partially prevented by IPC treatment ([Fig 2c](#pone.0234653.g002){ref-type="fig"}). Overall our data suggests that HK2 dissociation alone is insufficient to account for the reported deleterious effects of ischemia on mitochondrial respiration and OMMP.

![Effects of ischemia and *low pH plus G6P* treatments on mitochondrial respiration.\
Traces (a) are mean data of 8 independent experiments which are analysed further in panels b-c where data are presented as means ± SEM. The shadow area on the top graph (a) represents the range used to calculate respiration rates. (b) State 3 represents respiration in the presence of ADP. (c) Indirect assessment of OMMP by cytochrome c stimulation of mitochondrial respiration. Differences between groups were evaluated by a matched pair (± G6P low pH) two-way ANOVA with interaction followed by Holm-Šídák pos-hoc test to correct for multiple comparisons. \*, p \< 0.05; \*\*\*, p \< 0.001.](pone.0234653.g002){#pone.0234653.g002}

*In vitro* HK2 dissociation does not sensitize mitochondria to mPTP opening {#sec019}
---------------------------------------------------------------------------

Another hallmark of ischemia-induced changes to mitochondria is an increased sensitivity to mPTP opening. We investigated the effects of ischemia, IPC and mt-HK2 dissociation on the sensitivity of mPTP opening to \[Ca^2+^\] under both de-energized and energized conditions. The rate of A~520~ decrease induced by addition of Ca^2+^ was used to determine the extent of mPTP opening under de-energized conditions. Average traces (n = 5--6) in the absence and presence of CsA are shown in [Fig 3a](#pone.0234653.g003){ref-type="fig"} and [S3 Fig](#pone.0234653.s003){ref-type="supplementary-material"} respectively, while mean rates of swelling (± SEM) are reported in [Fig 3b](#pone.0234653.g003){ref-type="fig"}. Addition of a single bolus of Ca^2+^ to end-ischemia mitochondria caused a fast and large decrease in A~520~ that was not observed in pre-ischemia mitochondria, confirming previous data \[[@pone.0234653.ref038]\] that ischemia enhances the sensitivity of the mPTP to \[Ca^2+^\] and that IPC treatment was able to protect against this sensitization. As expected, incubation with CsA inhibited the mPTP regardless of the perfusion protocol ([Fig 3b](#pone.0234653.g003){ref-type="fig"}), but differences between groups were still observed. However, when HK2-depleted mitochondria were analyzed, no differences were observed relative to their matched controls, with one exception. The rate of *A*~520~ change was slightly lower in HK2-depleted end-ischemia mitochondria compared to normal end-ischemia mitochondria, although the response to CsA was similar in both groups.

![Effects of ischemia and *low pH plus G6P* treatments on mPTP opening under de-energized conditions.\
(a) Mitochondrial swelling associated with mPTP opening was triggered by addition of 83.5 μM free \[Ca^2+^\] and monitored by measurement of A~520~. Traces (a) are mean data of 5--6 independent experiments which are analysed further in panels b-c where data are presented as means ± SEM. (b) The initial swelling rate (*d/dt*~max~ *A*~520~) was calculated as the minimum of the first derivative of the absorbance traces and is shown as an absolute value. Cyclosporin A (CsA---0.2 μM) was used to inhibit mPTP opening. Individual and averaged traces are presented in [S3 Fig](#pone.0234653.s003){ref-type="supplementary-material"}. Differences between groups were evaluated by a matched pair (± G6P low pH) two-way ANOVA with interaction followed by Holm-Šídák pos-hoc test to correct for multiple comparisons. $\text{P}_{\text{interaction}}^{\text{without}\mspace{720mu}\text{CsA}} = 0.002$. \*\*\*, p \< 0.001. \#, p \< 0.05 vs matched group without CsA.](pone.0234653.g003){#pone.0234653.g003}

The sensitivity of mPTP opening to \[Ca^2+^\] was also evaluated under energized conditions using the calcium retention capacity assay. Average traces (n = 4--6) in the absence and presence of CsA are shown in [Fig 4a](#pone.0234653.g004){ref-type="fig"} and [S4 Fig](#pone.0234653.s004){ref-type="supplementary-material"}, respectively, while mean data (± SEM) for the calcium loading capacity are reported in [Fig 4b](#pone.0234653.g004){ref-type="fig"}. As expected, end-ischemia mitochondria accumulated less calcium compared to pre-ischemic mitochondria suggesting a higher sensitivity to pore opening, and IPC treatment attenuated this effect. CsA also attenuated mPTP opening but differences between groups were still present as was also observed under de-energized conditions. However, just as observed under de-energized conditions, the sensitivity of HK2-depleted mitochondria to mPTP opening was similar to control-matched mitochondria, regardless of the perfusion protocol or the presence of CsA. Taken together, these data imply that the increased sensitivity to mPTP opening observed after ischemia, like the changes in outer membrane permeability and respiration, must occur downstream of HK2 dissociation from mitochondria. We postulated that this might involve proteins such as Drp1 that are involved in mitochondrial fusion / fission and which we have previously proposed may provide a link between HK2 binding and modulation of mPTP activity \[[@pone.0234653.ref014]\].

![Effects of ischemia and *low pH plus G6P* treatments on the sensitivity to mPTP opening under energized conditions.\
(a) mPTP opening was evaluated by the calcium retention capacity assay with addition of 20 μM free \[Ca^2+^\] every 2 min. (b) Calcium-loading capacity was calculated as the sum of the number of Ca^2+^ pulses until mPTP opening, defined by an incomplete plateau before the next Ca^2+^ addition. Traces (a) are mean data of 4--6 independent experiments which are analysed further in panels b-c where data are presented as means ± SEM. CsA (0.2 μM) was used to inhibit mPTP opening and, individual and averaged traces can be found in [S4 Fig](#pone.0234653.s004){ref-type="supplementary-material"}. Differences between groups were evaluated by a matched pair (± G6P low pH) two-way ANOVA with interaction followed by Holm-Šídák pos-hoc test to correct for multiple comparisons. \*, p \< 0.05; \*\*, p \< 0.01; \*\*\*, p \< 0.001. \#, p \< 0.05 vs matched group without CsA.](pone.0234653.g004){#pone.0234653.g004}

Ischemia promotes Drp1 translocation to mitochondria *in vivo* but this is not prevented by IPC {#sec020}
-----------------------------------------------------------------------------------------------

Drp1 translocation from cytosol to mitochondria is known to occur upon reperfusion \[[@pone.0234653.ref039]\] but less is known about its localization during ischemia. In the light of the reported effects of Drp1 on the mPTP \[[@pone.0234653.ref040], [@pone.0234653.ref041]\] and the cardioprotection afforded by its inhibitor mdivi-1 \[[@pone.0234653.ref042]\], we investigated Drp1 association with mitochondria at the end of ischemia. In [Fig 5](#pone.0234653.g005){ref-type="fig"} we demonstrate that the levels of the mitochondrial fission receptor (Mff), which is responsible for Drp1 recruitment, were significantly lower in end-ischemia mitochondria compared to the pre-ischemic control ([Fig 5](#pone.0234653.g005){ref-type="fig"}, left). However, the amount of Drp1 present in end-ischemia mitochondria was higher than in their control counterparts ([Fig 5](#pone.0234653.g005){ref-type="fig"}, middle), suggesting that Drp1 may be recruited to sites other than Mff. IPC prevented neither the increase in mitochondrial Drp1 nor the decrease in Mff associated with mitochondria at the end of ischemia. These data imply that cardioprotection by IPC is independent of changes in Drp1 recruitment but this may not rule out an effect of IPC on the mitochondrial fission machinery since it has been shown recently that dynamin-2 (Dyn2) acts downstream of Drp1 recruitment in order to complete fission of mitochondrial membranes \[[@pone.0234653.ref043]\]. Thus, we measured the amount of Dyn2 levels present in the mitochondria. In contrast to Drp1, the amount of mitochondria-associated Dyn2 at the end of ischemia was only slightly higher than pre-ischemic mitochondria ([Fig 5](#pone.0234653.g005){ref-type="fig"}, right; p = 0.060), but IPC significantly decreased mitochondria-associated Dyn2 ([Fig 5](#pone.0234653.g005){ref-type="fig"}, right). This reduction reflects an effect of IPC on the recruitment Dyn2 to mitochondria since cellular Dyn2 levels remained unchanged ([Fig 5](#pone.0234653.g005){ref-type="fig"}, right, 'total').

![Effects of ischemia on the levels of mitochondrial fission proteins.\
The indicated proteins were collected either from total heart extracts or isolated mitochondrial fractions and resolved by SDS-PAGE followed by immunoblotting (for uncropped blots see [S5 Fig](#pone.0234653.s005){ref-type="supplementary-material"}). Ischemic damage was assessed indirectly by evaluating time to ischemic contracture \[[@pone.0234653.ref013]\]: 13.0 ± 0.8 min *vs*. 7.7 ± 1.2 min, p = 0.004, end-ischemia *vs*. IPC, respectively. Data in graphs are shown as mean ± SEM of 6 independent experiments. Differences between groups were run separately for 'total' and 'mitochondrial' datasets and were evaluated by one-way ANOVA followed by Dunnett's post-hoc test to correct for multiple comparisons. \*, p \< 0.05; \*\*, p \< 0.01.](pone.0234653.g005){#pone.0234653.g005}

Overall, our data show that although Drp1 recruitment alone cannot explain the increased sensitivity to mPTP observed after ischemia, it remains possible that it is the combination of Drp1 and Dyn2 associated with mitochondria that can regulate the sensitivity of the mPTP through changes in mitochondrial morphology \[[@pone.0234653.ref044]\]. In light of these observations, we investigated the effects of ischemia on IMM morphology.

Effects of ischemia on inner mitochondrial morphology {#sec021}
-----------------------------------------------------

### Validating the use of light scattering to detect changes in mitochondrial morphology {#sec022}

Previous work in this laboratory \[[@pone.0234653.ref027], [@pone.0234653.ref033]\] has shown that small changes in light-scattering (LS) of isolated heart mitochondria can be induced by ligands of the adenine nucleotide translocase (ANT) or sub-micromolar \[Ca^2+^\]. These LS changes are much smaller than those accompanying mPTP opening and occur in the absence of significant alterations in total organelle volume. Although it remains unclear how the conformation of the ANT leads to changes in LS, it is thought that it reflects changes in the inner mitochondrial morphology. The data of [Fig 6](#pone.0234653.g006){ref-type="fig"} confirm this by using transmission electron microscopy (TEM) to evaluate mitochondrial ultrastructure in parallel with LS measurements with the intention of using LS as a quantitative measure of any small changes in the inner membrane morphology that may accompany ischemia and HK2 loss. In these experiments we used Ca^2+^ and two ligands of the ANT, ADP and carboxyatractyloside (CAT), to modulate LS. ADP was chosen instead of bongkrekic acid because the latter binds irreversibly to the ANT whereas the effects of ADP can be reversed by CAT. Importantly, the effect of ADP is independent of ATP synthase activity since the buffer is lacking phosphate (Pi) and is supplemented with oligomycin (a specific ATP synthase inhibitor). We also confirmed that the ANT content of mitochondria was unaffected by ischemia and IPC ([S6 Fig](#pone.0234653.s006){ref-type="supplementary-material"}) and thus could not account for any changes in the effects of ANT ligands seen between mitochondria following these treatments.

![Effects of ANT ligands on the inner mitochondrial morphology in pre-ischemic mitochondria.\
a---monitoring of small fluctuations in light scattering in the presence of ANT ligands in pre-ischemia control mitochondria. b---A sub-set of samples of the light scattering experiments shown in (a) were chemically fixed and analyzed by TEM. Mitochondria were classified and counted accordingly to their inner membrane morphology by two independent operators blind to the treatment. *Type I*, mitochondria present evenly spaced cristae with regular width, ie. classical conformation; *Type II*, mitochondria present irregular cristae width but cristae are still thread-like, traversing from OMM to OMM. Spacing between cristae becomes irregular. *Type III*, mitochondria show a *Type II* configuration but at least two vesicular-like cristae are present. It reflects a combination between *Type II* and *Type IV* configurations. *Type IV*, mitochondria present rounded, nearly vesicular cristae without cristae traversing. Data in bars are presented as means of 2 independent experiments, each scored by two independent observers. Total number of mitochondria employed (193--347) and other morphometric parameters can be found on [S4 Table](#pone.0234653.s011){ref-type="supplementary-material"}. c---frequency distributions of morphometric data from TEM cross sections expressed relatively to the total number of analyzed mitochondria. Details about 'OMM perimeter' and 'Total membrane perimeter' can be found in Material and Methods and in the Supplemental Material. A Gaussian distribution was fitted to the data and independent fits between groups were compared to a global fit sharing the same *mean* by the extra sum-of-squares F test and p values adjusted for multiple comparisons through Holm-Šídák pos-hoc test. \*\*\*, p \< 0.001. Abbreviations: Base.--baseline, CAT---after carboxyatractyloside treatment, end-isch.---end-ischemia, Per.---perimeter.](pone.0234653.g006){#pone.0234653.g006}

[Fig 6a](#pone.0234653.g006){ref-type="fig"} shows a typical trace of such a LS experiment for pre-ischemia mitochondria. As expected, addition of a small amount of Ca^2+^ (1 μM free \[Ca^2+^\]), which is not sufficient to induce mPTP opening, caused a decrease in LS that could be reversed by addition of 0.2 mM ADP to induce the 'm' conformation of the ANT. The effect of ADP was itself rapidly reversed by addition of 5 μM CAT ([Fig 6a](#pone.0234653.g006){ref-type="fig"}). In [Fig 6b](#pone.0234653.g006){ref-type="fig"} we use TEM to confirm that the Ca^2+^-induced effects in LS are associated with changes in IMM morphology rather than total volume changes ([Fig 6c](#pone.0234653.g006){ref-type="fig"}). This conclusion assumes that mitochondria maintain a spherical shape after isolation, as reported by others \[[@pone.0234653.ref045]\]. We observed that IMM morphology could be broadly classified into four distinct categories, illustrated in [Fig 6b](#pone.0234653.g006){ref-type="fig"}. Ca^2+^ addition induced a clear transition from a *classical* conformation (Type I) towards rounded, nearly vesicular cristae without cristae traversing, ie. Type III-IV (p~*Type\ I*~ \< 0.001 and p~*Type\ III*~ \< 0.001, vs. baseline; [Fig 6B](#pone.0234653.g006){ref-type="fig"}). In addition to investigate IMM structures further, morphometric analysis of EM cross sections of the mitochondria was performed by determining the distribution of total membrane perimeter (including IMM, calculated as described in Material and Methods and [S7 Fig](#pone.0234653.s007){ref-type="supplementary-material"}) normalized to the OMM perimeter ([Fig 6c](#pone.0234653.g006){ref-type="fig"}, Ca^2+^ vs. baseline). These data show a shift towards higher values, in agreement with an IMM rearrangement towards vesicular cristae.

When ADP was added after Ca^2+^ to reverse the decrease in LS, TEM micrographs confirmed that this was accompanied by restoration of evenly spaced cristae with regular width, i.e. Type I ([Fig 6b](#pone.0234653.g006){ref-type="fig"}; p~Type\ I~ and p~Type\ III~ \> 0.05, vs. baseline). Interestingly, morphometric analysis showed that mitochondria presented a larger area in the presence of ADP ([Fig 6c](#pone.0234653.g006){ref-type="fig"}, left), but assuming a spherical shape upon isolation, one should expect a decrease in LS as a consequence of higher cross-section area. This is the opposite of what is observed ([Fig 6a](#pone.0234653.g006){ref-type="fig"}) and suggests that morphological changes have a stronger effect on LS compared to total volume changes, under these experimental conditions. Therefore, these observations indirectly confirm the robustness of our optical approach to monitor changes in inner membrane morphology. The full recruitment of ANT to its '*c'* conformation was achieved by addition of CAT. This caused a rapid drop in LS ([Fig 6a](#pone.0234653.g006){ref-type="fig"}) which was associated with a change in the inner membrane morphology towards Type III-IV ([Fig 6b](#pone.0234653.g006){ref-type="fig"}; p~*Type\ I*~ \< 0.001 and p~*Type\ III*~ = 0.013, vs. baseline). As might be expected, the total area and total membrane perimeter distributions more closely resemble those in the presence of Ca^2+^, in agreement with the IMM classification. Taken together these data confirm that under our experimental conditions, alterations in the IMM morphology induced by ligand-induced changes in ANT conformation are detected as small changes in LS as concluded previously \[[@pone.0234653.ref027], [@pone.0234653.ref033]\].

### Effect of ischemia and HK2 dissociation on mitochondrial ultrastructure {#sec023}

In [Fig 7](#pone.0234653.g007){ref-type="fig"} we present TEM data on the effects of ischemia on IMM morphology. To our surprise, end-ischemia mitochondria were observationally no different from pre-ischemic mitochondria and were mainly classified as Type I mitochondria (*classical*; [Fig 7a](#pone.0234653.g007){ref-type="fig"}). However, morphometric analysis did reveal that end-ischemia mitochondria were slightly, but significantly larger than pre-ischemic mitochondria ([Fig 7b](#pone.0234653.g007){ref-type="fig"}), consistent with a greater matrix volume as we have reported previously \[[@pone.0234653.ref046]\].

![Inner mitochondrial classification of pre-ischemia *vs*. end-ischemia mitochondria (a) and the corresponding morphometric analysis of EM cross sections (b).\
Data were processed as described in [Fig 6](#pone.0234653.g006){ref-type="fig"} and are shown as mean ± SEM of 2 independent experiments. Total number of mitochondria employed (193 for pre-ischemia and 412 for end-ischemia). \*, p \< 0.05; \*\*\*, p \< 0.001.](pone.0234653.g007){#pone.0234653.g007}

To explore any subtle differences in mitochondrial morphology induced by ischemia and IPC that might reflect changes in inner and outer membrane interactions or cristae structure that are not readily visible by TEM, we investigated the response of IMM to \[Ca^2+^\] and ANT ligands using the LS technique as described in [Fig 6](#pone.0234653.g006){ref-type="fig"}. This technique is also more readily quantifiable and much less labor intensive than using TEM ([Fig 8a](#pone.0234653.g008){ref-type="fig"}). The amplitude and rate change of LS induced by Ca^2+^ was considerably larger and faster in mitochondria from pre-ischemic hearts than those from end-ischemia hearts ([Fig 8b and 8e](#pone.0234653.g008){ref-type="fig"}). However, IPC treatment failed to re-establish the Ca^2+^-induced drop in LS to control values ([Fig 8b](#pone.0234653.g008){ref-type="fig"}). When ADP was added after Ca^2+^, the amplitude and rate change in LS were consistently higher in mitochondria from pre-ischemic hearts than those from end-ischemia hearts ([Fig 8c and 8f](#pone.0234653.g008){ref-type="fig"}). Interestingly, although the LS plateau achieved after Ca^2+^ addition by end-ischemia and IPC end-ischemia was similar ([Fig 8a](#pone.0234653.g008){ref-type="fig"}), IPC promoted a larger and faster ADP-induced change in LS compared to end-ischemia group ([Fig 8c and 8f](#pone.0234653.g008){ref-type="fig"}). Similarly, the amplitude and rate of CAT-induced change in LS were consistently lower in end-ischemia mitochondria compared to pre-ischemia mitochondria ([Fig 8d and 8g](#pone.0234653.g008){ref-type="fig"}).

![Effects of ischemia and *low pH plus G6P* treatments on the inner mitochondrial morphology.\
(a) Inner mitochondrial morphology was assessed indirectly by following small fluctuations in light scattering in the presence of ANT ligands. Traces (a) are mean data of 8 independent experiments which are analysed further in panels b-g where data are presented as means ± SEM. (b-d) The shadow area on the top graph represents the range used to calculate the amplitude of changes in *A*~520~. Amplitude values were calculated as the absolute difference between the final averaged value after the previous addition (or baseline if the first) and the last averaged value of the current addition. (e-g) Rates of change in *A*~520~ (*d/dt A*~520~) were calculated as the maximum (negative or positive) of the first derivative of the absorbance traces. Differences between groups were evaluated by a matched pair (± G6P low pH) two-way ANOVA with interaction followed by Holm-Šídák pos-hoc test to correct for multiple comparisons. \*, p \< 0.05; \*\*, p \< 0.01; \*\*\*, p \< 0.001.](pone.0234653.g008){#pone.0234653.g008}

Next, we investigated the LS responses of mitochondria depleted of HK2 by prior treatment with G-6-P at pH 6.3. The overall behavior of the HK-2 depleted mitochondria was similar to their control counterparts with the following exceptions ([Fig 8a](#pone.0234653.g008){ref-type="fig"}, dashed lines). First, the amplitude of the Ca^2+^-induced decrease in LS of HK2-depleted pre-ischemia mitochondria was lower than for un-depleted controls, but still higher than end-ischemia mitochondria ([Fig 8b](#pone.0234653.g008){ref-type="fig"}). Second, the rate of ADP-induced LS change of HK2-depleted IPC end-ischemia mitochondria was slower than for the same mitochondria without HK2-depletion, but still higher than end-ischemia mitochondria ([Fig 8f](#pone.0234653.g008){ref-type="fig"}).

Overall, our data reveal that ischemia, which decreases mt-HK2 binding, decreased the LS response to ANT ligands while IPC restored these effects. This implies that in parallel with its depletion of mt-HK2, ischemia reduces the coupling between ANT conformation and IMM, perhaps reflecting changes in inner and outer membrane interactions or cristae structure that are not readily visible by TEM, and that this effect is prevented by IPC. However, just as with the other parameters studied, modulating mt-HK2 alone had only a minor effect on this coupling, suggesting that events other than mt-HK2 dissociation occur *in situ* to prime mitochondria for mPTP opening on reperfusion.

Discussion {#sec024}
==========

The role of mt-HK2 in cardioprotection has been extensively studied in this \[[@pone.0234653.ref013], [@pone.0234653.ref018], [@pone.0234653.ref019]\] and other \[[@pone.0234653.ref020]--[@pone.0234653.ref023]\] laboratories. Pre-ischemic interventions, such as IPC, which prevent mt-HK2 dissociation afford substantial cardioprotection \[[@pone.0234653.ref013]\]. Indeed, we found a strong inverse correlation between the amount of mt-HK2 remaining at end of ischemia and the infarct size upon subsequent reperfusion. Although these studies have identified ischemia-induced events upstream and downstream of HK2 displacement, it has not been established whether mt-HK2 dissociation is the primary signal mediating the ischemia-induced changes to mitochondria that enhance mPTP opening on reperfusion. In the present investigation we have applied a battery of biochemical techniques and ultrastructure imaging tools to assess whether mt-HK2 dissociation alone is sufficient to reproduce some or all of the changes in mitochondrial function observed following ischemia. Our rationale is that, if prevention of HK2 dissociation from mitochondria is directly responsible for the attenuation of changes to mitochondria function at the end of ischemia, then its removal from IPC end-ischemic mitochondria should change these parameters back to those of non-preconditioned end-ischemic mitochondria. As in our previous work with permeabilized fibres \[[@pone.0234653.ref018]\], we used the combination of high \[G6P\] with low pH (6.3) to dissociate mt-HK2 *in vitro* during isolation of mitochondria which were then returned to normal isolation buffer to ensure that all assays were performed under identical conditions. This approach, which mimics ischemic conditions and is specific for HK isoform 2 ([Fig 1](#pone.0234653.g001){ref-type="fig"}), has advantages over peptide- or drug-based approaches, such as TAT-HK, AnP-HK or clotrimazole, that can exert non-specific effects \[[@pone.0234653.ref017], [@pone.0234653.ref018], [@pone.0234653.ref047], [@pone.0234653.ref048]\]. For example, in the case of synthetic peptides mimicking the HK2 binding peptide these might be carried through into the assay and mimic the bound HK2 in its effects on the mPTP. Indeed, isolated cardiac mitochondria of mice overexpressing GFP fused to this peptide show successful dissociation of mt-HK2 but retention of the recombinant protein \[[@pone.0234653.ref037]\].

It is important to note that our experimental design using isolated mitochondria allows us to make important observations which would extremely difficult, if not impossible, to perform using in intact cells / in vivo. First, our protocol dissociates HK2 from the mitochondria once isolated thus ensuring the absence of cytoplasmic factors that might exert effects on mitochondrial function or morphology that are secondary to mt-HK2 release. Second, we isolate mitochondria either from baseline or after a damaging insult ± protective regimen, allowing us to detect intramitochondrial differences that could account for increased sensitivity to pore opening upon mt-HK2 release since changes would be maintained in our experimental setup. In this context, we have previously shown \[[@pone.0234653.ref007], [@pone.0234653.ref019]\] that mitochondria isolated at end-ischaemia ± IPC show similar \[Ca^2+^\]~m~ accumulation while ischemic mitochondria show increased ROS production, which are well established mPTP triggers. The fact that complete removal of mt-HK2 does not change the sensitivity of the mPTP either in the baseline or the other tested groups, which have mitochondria with modified behaviour, suggests that mt-HK2 was not acting as "the pin of a grenade".

Loss of mt-HK2 binding is not the primary cause of OMM permeabilization, cytochrome c loss and mPTP sensitization during ischemia {#sec025}
---------------------------------------------------------------------------------------------------------------------------------

If it were the dissociation of mt-HK2 from mitochondria during ischemia that were directly responsible for cristae widening, OMMP, cytochrome c loss and mPTP sensitization during ischemia, it would be anticipated that removal of mt-HK2 *in vitro* with high \[G6P\] and low pH would mimic the effect of ischemia. However, in [Fig 2](#pone.0234653.g002){ref-type="fig"} we demonstrate that mt-HK2 dissociation on its own is not sufficient to induce OMMP and cytochrome *c* release. This implies that the entities responsible for OMMP are not pre-inserted in the mitochondria during ischemia such that they could initiate their action upon HK2 release. Indeed the only member of the Bcl2 family of proteins regulating OMMP that is changed in mitochondria following ischemia is Bcl-XL whose expression decreases \[[@pone.0234653.ref019]\], but IPC did not prevent this loss despite preventing cytochrome c release \[[@pone.0234653.ref018]\]. Thus, we propose that the ability of IPC to maintain mitochondrial morphology and OMM integrity during ischemia, and so facilitate cytochrome c retention, is not a direct effect of preventing mt-HK2 dissociation.

Similarly, *in vitro* dissociation of mt-HK2 from mitochondria did not sensitize them to mPTP opening ([Fig 5](#pone.0234653.g005){ref-type="fig"}) which is in stark contrast to the sensitization to mPTP opening seen in mitochondria from ischemic hearts, where mtHK2 dissociation also occurs. The fact that removal of mt-HK2 from IPC mitochondria does not increase mPTP activity to the level observed in end-ischemia mitochondria provides evidence that the IPC-mediated inhibition of mPTP opening is not caused directly by the bound HK2. This was somewhat unexpected in the light of published data on the role of HK in apoptosis \[[@pone.0234653.ref016], [@pone.0234653.ref049]\] and mPTP modulation \[[@pone.0234653.ref017]\] and implies that there is another regulatory factor involved in the sensitization of the mPTP by ischemia that is attenuated by IPC. This is unlikely to involve either calcium or ROS since we have shown that IPC modulates neither of these parameters in end-ischemic mitochondria \[[@pone.0234653.ref007]\] which led us to focus our attention on Drp1, whose association with I/R injury has been studied previously \[[@pone.0234653.ref039]\].

Drp1 recruitment during ischemia alone cannot explain mitochondrial sensitization to I/R injury {#sec026}
-----------------------------------------------------------------------------------------------

It has been reported that an increase in the intermembrane space occurs during mitochondrial remodeling in apoptosis and that this is dependent on Dynamin-related protein 1 (Drp1) \[[@pone.0234653.ref050]\]. Drp1 is a cytosolic protein that translocates to mitochondria to initiate fission \[[@pone.0234653.ref043]\]. Furthermore, a similar redistribution of Drp1 to mitochondria has previously been reported to occur upon reperfusion after ischemia \[[@pone.0234653.ref039]\]. These data are consistent with mitochondrial remodeling playing an important role in determining the outcome of I/R damage. An attractive hypothesis that we have discussed in more detail previously \[[@pone.0234653.ref014]\], is that mt-HK2 binding might prevent the association of cytosolic factors, such as Drp1, with mitochondria during ischemia and that it is these proteins that are the direct cause of the ischemic changes to mitochondria that activate the mPTP upon reperfusion. This would be consistent with the ability of the pharmacological inhibitors of Drp1, mdivi-1 (GTPase activity) and the peptide inhibitor P110 (Drp1-Fis1 interaction) to reduce infarct size in various models of cardiac I/R \[[@pone.0234653.ref042], [@pone.0234653.ref051]\], even though side-effects \[[@pone.0234653.ref052]\] and target requirements \[[@pone.0234653.ref053]\] are disputed. However, although we confirmed that ischemia did increase the recruitment of Drp1 to mitochondria, IPC failed to prevent this despite affording substantial cardioprotection ([Fig 5](#pone.0234653.g005){ref-type="fig"}). Thus, Drp1 binding to mitochondria alone cannot be responsible for ischemia-induced changes to mitochondria that prime them for mPTP opening on reperfusion. However, it should be noted that Drp1 activity and binding to mitochondria can be modulated by phosphorylation at various sites, as well as by other post-translational modifications such as sumoylation and nitrosylation, although there is considerable controversy over the effects, role and relevance of these modifications \[[@pone.0234653.ref040], [@pone.0234653.ref054], [@pone.0234653.ref055]\]. Furthermore, only modifications that inhibit the fission activity of Drp1 without causing its dissociation from mitochondria could account for our results and there is no clear evidence for such a mechanism. In addition, previous data from this laboratory have provided no evidence for a mitochondria-associated phosphorylated protein of the right size for Drp1 \[[@pone.0234653.ref011]\]. Another factor to consider is that Drp1 translocation is just one step in a cascade of events that occur in order to constrict and allow polymeric ring-like structures to severe mitochondria \[[@pone.0234653.ref043]\]. The process starts with ER-mediated constriction of mitochondria at pre-Drp1 sites in an Mff- and MiD49/51-independent manner, followed by Drp1 recruitment by its adaptor proteins and finishes with Dyn2 recruitment and assembly to complete fission \[[@pone.0234653.ref043]\]. Interestingly, ablation of Mfn2, a mitochondrial adaptor protein necessary for ER-mitochondria tethering, increases infarct size \[[@pone.0234653.ref056]\]. Indeed, modulation of any of these checkpoints \[[@pone.0234653.ref051], [@pone.0234653.ref057], [@pone.0234653.ref058]\], or just inhibition of the last step, such as inhibition of Dyn2 by dynasore \[[@pone.0234653.ref059]\], is sufficient to attenuate I/R injury. Our data from IPC treatment suggests that mt-HK2 cardioprotective mechanism could be due, in part, to prevention of mitochondrial recruitment of Dyn2 rather than Drp1. However, the relationship between HK2 binding to mitochondria and changes in Drp1/Dyn2 recruitment remains unclear. It is unlikely that mt-HK2 binding to the OMM masks sites that bind Drp1 since, if this were the case IPC, which reduces mt-HK2 loss, should prevent the recruitment of Drp1 during ischemia which it did not. Nevertheless, our data would be consistent with mt-HK2 attenuating the binding of Dyn2 that follows recruitment of Drp1. We cannot rule out the possibility that the changes in mt-HK2 are secondary to changes in the recruitment of both Drp1 and Dyn2 and that mt-HK2 plays no role in modulating mitochondrial morphology and mPTP sensitivity during ischemia. However, our IMM morphometric analysis, discussed further below, suggests that contact sites between the inner and outer membranes, which are disrupted in ischemia, may be involved in modulating mPTP sensitivity and hence in cardioprotection. Thus, dissociation of mt-HK2, which is known to associate with contact sites, could co-operate with Drp1 and Dyn2 recruitment to cause their destabilization in ischemia. IPC attenuates destabilization by preventing mt-HK2 dissociation.

Ischemic attenuation of mitochondrial morphology changes---Role of contact sites {#sec027}
--------------------------------------------------------------------------------

Modulation of IMM morphology by ANT ligands in our LS experiments ([Fig 8](#pone.0234653.g008){ref-type="fig"}) are thought to be a surrogate marker of contact site lability \[[@pone.0234653.ref026]\]. Thus, we propose that the decreased magnitude and slow rate of ANT ligand-induced changes in LS exhibited by mitochondria from ischemic hearts reflect lower contact site stability induced by ischemia and their maintenance by IPC. Indeed, Bakker et. al \[[@pone.0234653.ref060]\], through the use of stereological methods, demonstrated that the ability of heart mitochondria to form contact sites is lost during ischemia, worsening the injury at reperfusion \[[@pone.0234653.ref060]\]. Our own data showing reduced rates of the creatine phosphate shuttle during reperfusion after prolonged ischemia and the prevention of this effect by IPC are consistent with this proposal \[[@pone.0234653.ref013]\]. Furthermore, using permeabilized cardiomyocytes we were able to show that mt-HK2 dissociation from mitochondria using G6P and low pH attenuated creatine shuttle activity implying that stabilization of contact sites with mt-HK2 is important for the efficient function of the shuttle \[[@pone.0234653.ref013]\]. However, removal of mt-HK2 had no significant effect on the Ca^2+^ and ANT ligand-induced effects on LS of isolated mitochondria ([Fig 8](#pone.0234653.g008){ref-type="fig"}), implying that these morphological changes are reflecting more than just contact site destabilization. The TEM data of [Fig 6](#pone.0234653.g006){ref-type="fig"} confirm this and show that LS changes are accompanied by changes in the cristae structure and IMM morphology. IMM remodeling is required during fission to ensure the proper segregation of IMM at both ends of the Drp1 constriction stalk before a fission event. It is possible that the reduced LS responses seen in mitochondria at the end of ischemia may indicate that, despite binding of Drp1 ([Fig 5](#pone.0234653.g005){ref-type="fig"}), the mitochondria have undergone sub-optimal fission \[[@pone.0234653.ref061]\]. This process is known to lead to cytochrome c loss and so IPC, by maintaining mitochondrial membrane contact sites may ensure IMM remodeling is complete, thus preventing loss of cytochrome c.

Limitations of the current study and future avenues {#sec028}
---------------------------------------------------

Although the approach chosen to dissociate mt-HK2 in the current investigations can be considered physiological-like (low pH and high levels of G6P) it was performed *ex vivo* and outside the cellular context. While this gave us control over the dissociation process it does not allow exploration of any potential mechanistic link between mt-HK2 release and Dyn2 translocation. However, the role and regulation of fusion / fission proteins in mPTP opening is complex and controversial and to investigate this interaction more fully is beyond the scope of our present study. We provide data that are suggestive of an involvement of Drp1 and Dnm2 which we hope may be a stimulus for further studies such as investigating the signaling pathway(s) that modulate mt-HK2 binding and Dyn2 translocation to mitochondria during ischemia and IPC. It might also be illuminating to employ genetic models of altered HK/HK2 expression, but their utility is subject to significant limitations. First, overexpression of HK2 generally increases the cytosolic pool rather than promoting mitochondrial association of HK2 \[[@pone.0234653.ref062]\], consequently there is an increase in glycogen content \[[@pone.0234653.ref063]\], which is considered a cardioprotective regimen. Second, knock-out could produce profound metabolic effects that might mask the effects of acute mt-HK2 release on mitochondrial morphology / function. In this regard, there is currently a need for the development of more efficient approaches to promote acute mt-HK2 release as the available drug- and peptide-based procedures have significant side-effects \[[@pone.0234653.ref015], [@pone.0234653.ref017], [@pone.0234653.ref018], [@pone.0234653.ref064]\].

Although we observed a concomitant association of Dyn2 with mitochondria when mt-HK2 dissociates during ischemia, and that this effect is prevented by IPC, we cannot rule out the possibility that the effect is independent of mt-HK2 release and represents a parallel effect rather than a downstream event. Similarly, it would be of major importance to evaluate in greater detail how Dyn2 and/or Drp1 modulate mitochondrial ultrastructure which was presently only assessed using light scattering.

Conclusion {#sec029}
==========

We have shown that release of mitochondrial-bound HK2 *in vivo* during ischemia does not affect end-ischemia mitochondrial function directly. Rather, we propose the effects are indirect through destabilization of contact sites between mitochondrial inner and outer membranes. These are thought to be the site of HK2 binding and are important for the efficient operation of the creatine shuttle. IPC, by maintaining mt-HK2 binding, stabilizes these contact sites preventing their disruption during ischemia. Ischemia also causes the recruitment of Drp1 and Dyn2 to mitochondria that together mediate changes in mitochondrial morphology and cristae structure to enhance cytochrome c release and sensitizes mPTP opening on reperfusion. We propose that mt-HK2 binding to contact sites may prevent Drp1-mediated recruitment of Dyn2 thus explaining how IPC exerts its cardioprotective effects.

Supporting information {#sec030}
======================

###### Diagram depicting the experimental design and protocol for mitochondrial preparation and treatment.

Note that the dissociation protocol used to release mitochondrial-bound HK2 occurs prior to data acquisition and that dissociation agents are absent from the washing buffers.

(TIFF)

###### 

Click here for additional data file.

###### Effect of washing buffer pH on mt-HK2 dissociation assessed through the activity of the remaining mt-HK.

Total HK activity of mitochondria pre-treated with dissociation buffer during isolation protocol (a); data are presented as mean ± SEM of 4 independent experiments on different mitochondrial preparations. Differences between groups were evaluated by a matched pair (± low pH) t Student's test. (b) uncropped and representative immunoblot against HK2 on isolated mitochondrial fractions. (c) Coomassie staining of membrane shown in (b). The loading control for membrane in (b) is shown on [S6b Fig](#pone.0234653.s006){ref-type="supplementary-material"} (the mitochondrial protein ANT). (d) uncropped immunoblots against HK2, HK1 and ANT as shown on main [Fig 1](#pone.0234653.g001){ref-type="fig"}.

(TIFF)

###### 

Click here for additional data file.

###### Protective effects of 0.2 μM cyclosporine A (CsA) on the sensitivity of mPTP opening under de-energized conditions.

Mitochondrial swelling associated with mPTP opening was triggered by addition of 83.5 μM free Ca^2+^ and monitored by measurement of A~520~ (a). Data are presented either as mean of 5--6 independent experiments (b~i~-c~i~) or overlaid with individual runs (b~ii~-c~ii~) for the perfusion groups in the study (pre-ischaemia---bi, bii; end-ischaemia---ci, cii; and, IPC end-ischaemia---di, dii).

(TIFF)

###### 

Click here for additional data file.

###### Protective effects of 0.2 μM CsA on the sensitivity of mPTP opening under energized conditions.

mPTP opening was evaluated by the calcium retention capacity assay with addition of 20 μM free Ca^2+^ every 2 min (a). Data are presented as mean independent experiments (b~i~-c~i~) or overlaid with individual runs (b~ii~-c~ii~) for the perfusion groups in the study (pre-ischaemia---bi, bii; end-ischaemia---ci, cii; and, IPC end-ischaemia---di, dii).

(TIFF)

###### 

Click here for additional data file.

###### Representative western blots for [Fig 5](#pone.0234653.g005){ref-type="fig"}.

Dyn-2 (a, b), Drp1 (a, b) and Mff (c) data shown on [Fig 5](#pone.0234653.g005){ref-type="fig"}. Total extracts are shown in (a) while mitochondrial fractions are shown in (b), for Dyn-2 and Drp1. For Mff only mitochondrial fractions were analyzed. GAPDH was used as loading control for the total extracts while VDAC was used for mitochondrial fractions instead. The vertical white bar along the blots on (a) and (b) indicate that although the samples were in the same membrane they were not next to each other (non-relevant samples are omitted in the picture).

(TIFF)

###### 

Click here for additional data file.

###### Effect of ischemia and "low pH + G6P" on the levels of mitochondrial ANT protein.

Data are presented as mean ± SEM of 6--8 independent mitochondrial fraction samples (a). For details on the use of "low pH + G6P" please see the [Material and methods](#sec002){ref-type="sec"} section. Differences between groups were evaluated by a matched pair (± G6P low pH) two-way ANOVA with interaction followed by Holm-Šídák pos-hoc test to correct for multiple comparisons. (b) representative western blot of the analysis in (a). (c) loading control of the western blot shown on (b) by Coomassie staining.

(TIFF)

###### 

Click here for additional data file.

###### EM segmentation pipeline.

Example of the image-processing pipeline for mitochondrial membranes segmentation in EM micrographs. A---original; B---band pass filter; C---Otsu threshold; D---particle size filtering.

(TIF)

###### 

Click here for additional data file.

###### Hemodynamic data monitored before ischemia of hearts used for mitochondrial isolation.

Hearts were perfused according to the protocols described in the Material and Methods section. All the data presented in the table correspond to hemodynamic function recorded prior to the index ischemia at the end of the stabilization period. Data for each parameter were analyzed by a one-way ANOVA followed by Holm-Šídák pos-hoc test to correct for multiple comparisons. \*, p\<0.05 vs pre-ischemia or ischemia. Abbreviations: EDP---end-diastolic pressure; IPC---ischemic preconditioning; Isch.---ischemia; RRP; rate pressure product; SP---systolic pressure.

(DOCX)

###### 

Click here for additional data file.

###### Parameters relating to ischemic contracture of hearts used for mitochondrial isolation.

All the data presented in the table were obtained during the index ischemia. T0 indicates time at which rigor started; Amax, rigor maximum amplitude. Data for each parameter was analyzed by a two-tail Student's t test. \*, p\<0.05. Abbreviations: IPC---ischemic preconditioning; n.a.---not applicable.

(DOCX)

###### 

Click here for additional data file.

###### Hemodynamic data monitored during reperfusion for the group of hearts used to study infarct size.

Hearts were perfused according to the protocols described in the Material and Methods section. All the data presented in the table correspond to hemodynamic function recorded after 5 and 60 min of reperfusion. Infarct size was assessed by the TTC staining 120min after starting reperfusion. Data for each parameter were analyzed by a two-tail Student's t test. \*, p \< 0.05; \*\*\*, p \< 0.001. Abbreviations: AAR---area at risk; IPC---ischemic preconditioning.

(DOCX)

###### 

Click here for additional data file.

###### Morphometric data from EM micrographs of isolated mitochondria incubated with different ANT ligands.

Data are presented as mean ± SD and differences relatively to baseline were analyzed by a one-way ANOVA followed by Dunnet's pos-hoc test to correct for multiple comparisons. \*\*\*, p\<0.001 vs baseline.

(DOCX)

###### 

Click here for additional data file.

ANT

:   adenine nucleotide translocator

AUC

:   area under the curve

BKA

:   bongkrekic acid

CAT

:   carboxyatractyloside

CrK

:   creatine kinase

CsA

:   cyclosporine A

Drp1

:   dynamin-related protein 1

Dyn2

:   dynamin 2

G6P

:   glucose-6-phospate

GMS

:   5 mM L-glutamate, 2 mM L-malate and 5 mM succinate

HK

:   hexokinase

I/R

:   ischemia-reperfusion

IMM

:   inner mitochondrial membrane

IPC

:   ischemic preconditioning

Mff

:   mitochondrial fission factor

mPTP

:   mitochondrial permeability transition pore

mt-HK

:   mitochondrial-bound hexokinase

OMM

:   outer mitochondrial membrane

OMMP

:   outer mitochondrial membrane permeabilization

PCr

:   phosphocreatine

TEM

:   transmission electron microscopy
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Partly

Reviewer \#4: Yes

Reviewer \#5: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

Reviewer \#5: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

Reviewer \#5: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: Yes

Reviewer \#5: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: In this report, the authors study the role of in vitro HK2 dissociation in mitochondrial functions after ischemia. The authors conclude that in vitro HK2 dissociation alone does not replicate ischemia induced effects of mitochondrial function and morphology. The experiments appear to be carefully performed and data presentation is extensive. The paper, however, presents little that is unexpected, is largely descriptive and correlative, and leaves gaps that limit the impact and credibility of the conclusions. The study unfortunately does not examine this signaling axis in an in vivo system and thus the relevance of the finding is of minimal impact. There are also shortcomings in the experimental design.

1\. It has been established by this lab and others that mt-HK2 provides protection against ischemic stress (eg., PMID 21527739, 23836898, 21071708) and, in general, it is not surprising that inhibition of protective pathway is not sufficient to induce pathophysiological responses. Indeed, HK2 KO mice (heterozygous) are viable, fertile, and grew normally (PMID 10428828). It has also been demonstrated that at baseline, HK2+/− mice have normal cardiac function but display lower systolic function after I/R (PMID 21071708). Thus novelty regarding mt-HK2 is somewhat incremental.

2\. This paper uses low pH and G6P to dissociate HK2 from isolated mitochondria, solely relying on this intervention. The specificity of the treatment is not demonstrated although the treatment would have other effects on isolated mitochondria. More specific interventions should also be utilized. For instance mt-HK2 dissociation peptides have been widely used by many investigators in cells, ex vivo heart and in vivo heart (PMID 15574336, 21527739, 31570704) and this should be more selective, especially in isolated mitochondria.

3\. A number of relevant work studying the effect of mt-HK2 in the heart (for examples, some of papers cited in the above) are not even mentioned in this manuscript. The findings of these papers as well as the contradictions they might generate should be adequately discussed. In addition, there are conflicting reports regarding the role of mitochondrial fusion/fission in I/R injury. For example, Ikeda et al (PMID 25332205) showed that the infarct size after I/R was significantly greater in cardiac-specific Drp1 heterozygous knockout than in control mice. This study also showed that mdivi-1 has direct cell-protective effects on cardiomyocytes independent of Drp1. Studies using Mfn-2 knockout suggest that Mfn-2, a fusion protein, serves to predispose cells to mitochondrial permeability transition and to trigger cell death (PMID 21245373, 22037195).

The authors need to describe about these issues in a balanced fashion.

4\. The effect of mt-HK2 dissociation is examined only in isolated mitochondria in this study. Although this allows precise examination of the effect of mt-HK2 dissociation on mitochondrial function, it would not mimic the environment in vivo. Thus in vivo analysis would be required to strengthen this paper.

Furthermore, what condition shown here with low pH and G6P in isolated mitochondria from ischemic heart can mimic the stage of ischemic heart diseases? G6P accumulation and lower pH occur during ischemia while calcium overloading and mPTP pore opening (figures 3 and 4) occur upon reperfusion. mt-HK2 is already decreased by ischemia through G6P accumulation and lower pH, and is further decrease in isolated mitochondria with low pH and G6P relevant as a model for vivo I/R? Does reperfusion further decrease the level of mt-HK2? If so what is the mechanism?

5\. Analysis of mitochondrial morphology is also carried out only in isolated mitochondria. It is not clear what is expected in the experiment without other cellular compartments, especially cytosol. For instance, Drp1 is largely cytosolic (97%) and translocates to mitochondria by post-transcriptional modifications, and this aspect is lost in isolated mitochondria experiments. Another reason why mitochondrial morphology should also be examined in the heart (not isolated mitochondria), for example, by electron microscopic analysis in heart sections, is that conventional mitochondrial fractionation might not efficiently collect fragmented- and small mitochondria (PMID 25600785).

6\. Other mitochondrial fission proteins (Fis1, Mid49 and Mid51) should also be examined. How about mitochondrial fission proteins (Mfn1/2, Opa1)?

7\. VDAC is used to normalize Mff, Drp1 and Dyn2 levels in the mitochondrial fraction (Figure 5) . If OMMP is induced by ischemic stress, inner mitochondrial protein would be more appropriate as a control.

8\. Representative Western blots should be shown.

Reviewer \#2: Here, the authors test whether the loss of HK2 from mitochondria is sufficient for the effects associated with this process on MPTP. Recapitulation of the enhanced G6P/reduced pH conditions associated with ischemia dissociated the vast majority of HK2 from mitochondria isolated from pre- and -end ischemic hearts as well as PCed hearts. However, this did not alter respiration, OMMP, or mPTP opening in any of the groups, which still exhibited the expected changes between pre, end and PC hearts. Mitochondrial translocation of Drp1 and increased mitochondrial size was observed in the end-ischemic group revealed translocation to mitochondria during ischemia but was unaffected by PC or loss of HK2. The authors conclude that loss of HK2 during ischemia is not responsible for all the observed mitochondrial effects, and that other mechanisms are at play.

This is a thorough, well designed study that uses multiple, overlapping indices to truly address an important question that has remined in the field for quite some time.

The study is well controlled, sufficiently powered, and the statistical analyses are appropriate and rigorous

Comments

1\) Protein expression of Drp1 is not necessarily indicate of activity. Assessment of Drp1 Ser616 phosphorylation would provide more insight in this regard. For example, PC may not alter translocation, but it might alter phosphorylation.

2\) The Westerns should be included with the quantified data in the main figures. It would also be helpful if the dilution used could be included in the methods.

Reviewer \#3: In this paper, Pereira et al. studied whether HK2 release from the mitochondria is the primary signal mediating ischemia-induced mitochondrial dysfunction. They isolated mitochondria from Langendorff-perfused rat hearts before and after 30 min of ischemia ± ischemic preconditioning (IPC). They then subjected the isolated mitochondrial to in vitro dissociation of HK2 by incubation with glucose-6-phosphate at pH 6.3. HK2 dissociation had no effect on their cyt-c release, respiration or mPTP opening. They also noted no major ultrastructural differences between pre- and end-ischemia mitochondria, but the amplitude of changes in light scattering was reduced in the mitochondria after end-ischemia. They also showed more Drp1 in end-ischemia mitochondria, but IPC failed to prevent this increase but did decrease mitochondrial-associated dynamin 2. They concluded: "In vitro HK2 dissociation alone cannot replicate ischemia-induced effects on mitochondrial function implying that in vivo dissociation of HK2 modulates end-ischemia mitochondrial function indirectly perhaps involving interaction with mitochondrial fission proteins. The resulting changes in mitochondrial morphology and cristae structure would destabilize outer / inner membrane interactions, increase cyt-c release and enhance mPTP sensitivity to \[Ca2+\]."

These studies are interesting and will advance the field. However, the authors solely relied on G6P and pH of 6.3 to dislocate HK2 from the mitochondria. These processes have other effects, including inhibition of hexokinases. The authors should have used better methods to dislocate HK2 form the mitochondria, including the use of clotrimazole or a peptide specific to the mitochondrial binding domain.

Additionally, the actual western blots measuring protein levels are missing in some figures.

Reviewer \#4: Summary: The investigators showed previously that cardiac ischemia results in HK2 dissociation from mitochondria with concomitant loss of cyt c and induction of mPTP opening on reperfusion. The loss of HK2 is thought to be due to the increase in glu-6-P and decrease in pH during ischemia caused by increased glycolysis. IPC is somewhat protective with the hypothesis that IPC might reduce the dissociation of HK2 from mitochondria due to less glycolysis during ischemia with subsequent improved cardiac function on reperfusion and a decrease in infarct size. Cyt c release and the juxtaposition of OMM and IMM and their components VDAC and ANT, and of HK2 with VDAC, figure into sensitization of mPTP opening with IR injury. Using an isolated mitochondrial model, the authors tested the hypothesis that the loss of HK2 attachment to mitochondria is the major factor in predisposing to cell damage because IPC reduces detachment of HK2 from mitochondria. To rule out cytosolic factors that might interact with HK2 or the OMM they examined mitochondria in isolation. In their model they isolated mitochondria from non-ischemic isolated hearts and from hearts subjected to IR injury ± IPC. In each group of hearts HK2 was artificially dissociated from mitochondria using an acidic buffer (pH 6..3) plus an excess of glu-6-P. They then measured common indices of mitochondrial function and integrity, such as respiration, CRC (Fura-FF), membrane potential, and OMM and cristae morphology (by light scattering-swelling assay and TEM) with manipulation of ANT conformations using CAT. In other experiments they did not artificially dissociate HK2 from mitochondria, but used western blotting after IR± IPC to assess changes in mitochondrial amounts of HK2, ANT, Dyn2 and Drp1., using antibodies against these proteins, and measured activities of HK and citrate synthase.

They found that THE chemically induced dissociation of HK2 did not mimic the mitochondrial changes found after IR injury as there was no effect on cyt c release, respiration, or proneness to mPTP opening. So, alternatively, they suggested that there is an intermediate step during IR injury that leads to HK2 dissociating from mitochondria. They furnish evidence that IR modulates the mitochondrial binding of two other proteins, Drp1 and Dyn2, based on their finding that Drp1 increased in mitochondria after ischemia (not affected by IPC) but that an increase in Dyn2 was reduced by IPC. From this they speculated that Drp1 and Dyn2, interacting with HK2 on the OMM, cause morphological changes that destabilize the OMM to enhance cyt c release and mPTP sensitivity to elevated (matrix) calcium. The authors speculate that Drp1 translocation from the cytosol to mitochondria occurs during ischemia and this in turn recruits Dyn2 to the OMM where it is tethered if HK2 is no longer bound. The binding of Dyn2 in the absence of HK2 is proposed to destabilize the OMM and IMM. The authors conclude that normally HK2 binding to contact sites on the OMM may prevent Drp1 from recruiting Dyn2 and that IPC is cardioprotective because it prevents the increase in Dyn2 in mitochondria. They concede that HK2 dissociation and association of Dyn2 may be unrelated, but parallel events in IR injury but posit that Drp1 and Dyn2 cannot associate with the OMM if HK2 is present.

I have only a few comments:

1\. The manuscript is well written with good description of all the methods, results and statistics. The discussion is balanced and admits that the connection between HK2 dissociation and Dyn2 association is unclear and needs to be better discerned. The plan to isolate the role of HK2 dissociation in IR injury by simulating HK2 dissociation in isolated mitochondria devoid of cytosolic factors after IR injury was good.

2\. How do you explain the almost complete loss of HK2 content with only a 50% reduction of HK activity? Is there HK1 activity associated with bound HK1?

3\. Fig. S4 should be placed in the main text as it is pertinent to the role of this protein.

4\. The investigators did an extraordinary amount of work with the LS technique and TEM to assess the morphological changes (Figs. 6-8) after ANT ligand treatment and artificially induced HK2 dissociation after ± IR ± IPC. The problem is I don't clearly understand the connection of this data with the morphological effects of HK2 dissociation, or not, and the roles of Drp1 and Dyn2. Can you please clarify this better for the reader? I'm referring to lines 557-564.

5\. What is the Drp1 or Dyn2 or Mff distribution pattern in the pre ischemia, end ischemia and IPC, end ischemia in the presence and absence (acidic pH +glu-6-P) of HK2?

6\. Did you correlate LS data and IMM morphology data (TEM data) during IPC? This could have given some insight into the effect of IPC on the preservation of mitochondrial cristae dynamics (if any?). In addition, do you have results on the presence and absence (acidic pH + G6P) of HK2 during IPC? This could furnish information on the effect of HK2-dependent Drp1/ Dyn2 recruitment to mitochondria.

7\. Fig. 8b and 8d: Shouldn't these numbers be negative?

Reviewer \#5: Hexokinase II (HKII) catalyzes the conversion of glucose to glucose-6-phosphate (G6P). Studies have shown that HKII inhibits cell death including during myocardial ischemia-reperfusion injury. During ischemia, mitochondrial HKII dissociates from mitochondria, and the extent of mitochondrial HKII dissociation is correlated with cell death. However, it remains unclear whether the dissociation of HKII from mitochondria is correlative or causative with respect to cardiac damage during ischemia-reperfusion. Using isolated mitochondria from rat hearts subjected to ischemia ex vivo, Pereira et al. report that HKII dissociation alone is not sufficient to account for morphological and functional abnormalities following ischemia.

Comments:

1\. Fig. 1. First, the HKII Western data in Supp Fig 1 should be included in Fig. 1. Second, is the persisting HK activity in low pH + G6P specific to HKII? If it is, this would suggest that not all the HKII has been dissociated? Is there a specific HKII inhibitor that could be used to show this residual is not attributable to remaining HKII? Third, if this residual HK activity is real and attributable to HKI (as you posit), is HKI also known to inhibit cell death? If so, levels of HKI should also be assessed by Western. The reason for asking these questions is that the rest of the study shows largely negative data. In order to interpret this negative data definitively, it is necessary to know that low pH + G6P is, in fact, inactivating protective mechanisms resulting from all HKs at the mitochondria.

2\. Fig. 3b. Please check the comparison in the ischemia group (red bars) between normal and low pH + G6P (all no CsA). Is this really 3 stars?

3\. Fig. 5. I do not understand how these data showing how ischemia or ischemic preconditioning affects the abundance of various mitochondrial fission components at the mitochondria relate to the rest of the story, which is about HKII dissociation from mitochondria not playing a causal role in cell death. These data are not really developed. Unless I missed your point, why include this figure in the paper?

4\. Figs 6 and 7. This is validation of an approach. It is important, but could be placed in supplemental data. The actual data using this approach, shown in Fig. 8, is what belongs in the main paper.

5\. Fig. 8. I understand your main point that the normal versus low pH + G6P pairs showed no difference. But, why was delta-Abs520 under Ca2+ treatment conditions not rescued by IPC compared with ischemia alone?

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

Reviewer \#3: No

Reviewer \#4: Yes: David F. Stowe, MD, PhD and Jyotsna Mishra, PhD

Reviewer \#5: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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15 Dec 2019

Reviewer \#1

General Comments

We are pleased to see that the Reviewer, although critical, recognizes that the experiments have been "carefully performed and data presentation is extensive". We were unsure why the reviewer feels that the paper presents little that is unexpected. A key message of the paper is that despite the strong correlation between mt-HK2 binding at the end of ischemia and cardioprotection, this effect cannot be a direct effect of HK2 on the mitochondrial permeability transition and must be through downstream mechanisms. We think it is a little strong to say this was expected since there had been extensive literature on the role of HK2 on mPTP function in the literature. It is also a little harsh to say the data are largely descriptive; there are extensive quantitative data to back up the conclusion that HK2 itself is not the key regulator of mPTP opening in ischemia / reperfusion. We also take issue with the criticism that a major shortcoming is the signalling axis in vivo. We previously addressed this and showed that the extent of HK2 dissociation during ischemia could be explained by the magnitude of the drop in pH and build up of glucose-6-P during ischemia. The purpose of this paper was to establish how the change in HK2 binding related to the sensitivity of the mPTP to opening at the end of ischemia and we believe we do this convincingly.

Specific Comments

1\. We would agree with the reviewer that there is much published data to support the cardioprotective role of mtHK2 and it was our own published work (PMID 23329796, 23525412, 25204670) on this that has led to the present studies. However, what these earlier studies do not address is whether the protective effects of mtHK2 are a result of direct inhibition of mPTP opening on reperfusion. Here we show that this cannot be the case and we would suggest that this is a very significant observation that is more than incremental. Moreover, genetic ablation rather than acute mt-HK2 dissociation will probably induce metabolic remodelling in the cardiac tissue that is secondary to HK2 redistribution in the cell, masking the real effect of acute mt-HK2 dissociation.

2\. The reviewer is critical of our use of low pH and G-6-P to dissociate mtHK2 and suggest the use of HK2 dissociating peptides. However, our previous studies have shown that the use of such peptides is open to criticism, especially in vivo, because of non-specific effects (PMID 23329796). More importantly, we have previously shown that the mechanism of HK2 dissociation during ischemia involves the observed decrease in pH and increase in \[G-6-P\], both of which are attenuated by ischemic preconditioning. Thus, we would argue that the use of low pH and G-6-P to dissociate HK2 in isolated mitochondria is entirely appropriate.

Additionally, we are not sure what the reviewer meant by "the treatment would have other effects on isolated mitochondria". The combination of low pH and G-6-P is: 1) a physiological phenomenon; 2) we have previously demonstrated (PMID: 23525412), and confirm here, that none of the effects alone can affect mitochondrial respiration; 3) the dissociation protocol occurs prior to assaying mitochondrial function, decreasing any interference during data acquisition; 4) the dissociation protocol is brief and occurs at low temperature having negligible effects on mitochondrial metabolism.

We also think that the use of a peptide-based approach is not straight forward. For example: solubility of peptides in aqueous solutions can be challenging, lowering their effective concentration; 2) reaction or sample vessels require coating to prevent the peptides to bind to their surface; 3) peptides and peptides-based approach are prone to proteolysis both by internal and external proteases present during mitochondrial isolation.

Overall, we agree with the reviewer that peptide-based approaches are certainly useful in several biological setups; however, we are confident that our approach is as valid if not better suited for the present investigations.

3\. The reviewer suggests that we cite more earlier papers on mtHK2 and discuss their data in relation to our present studies. We have previously discussed this work in our earlier papers cited here (PMID 23329796, 23525412, 25204670) but now also refer to data implicating HK2 in the regulation of mPTP opening in other systems. Please see lines 93-95 in the revised manuscript. We suggest that a wider ranging discussion on the possible role of the fission fusion machinery in regulating the mPTP is outside the scope of the present paper but in line 718 we now refer to an earlier review in which we do this (PMID 25204670). Furthermore, in response to Reviewer \#2 we do now discuss the possible role of Drp1 phosphorylation. This is provided in lines 726-733 of the revised manuscript.

4\. The reviewer suggests that in vivo analysis of mtHK2 dissociation would strengthen the paper, but we are not sure in what way. We and others have already provided evidence that the extent of mtHK2 dissociation in vivo at the end of ischemia correlates with the damage on reperfusion and on the sensitivity of mitochondria isolated at the end of ischemia to mPTP opening and cytochrome c release. The purpose of this paper is to establish whether the dissociation of mtHK2 alone is what mediates these effects. In our opinion, this is best done with isolated mitochondria where interference by other outer membrane and mPTP interacting factors might complicate data interpretation.

The other point raised by the reviewer relates to the fact that we are measuring changes occurring in ischemia whereas the damage through mPTP opening occurs on reperfusion. This is a critical point. We showed previously (PMID 18356542) that it is the mitochondrial state at the end of ischemia that determines their sensitivity to mPTP opening on reperfusion. Thus, mitochondria isolated from ischemic hearts are much more sensitive to mPTP opening than those from control hearts. However, ischemic or pharmacological preconditioning attenuates this sensitisation (PMID 18356542, 20558443) and thus leads to less mPTP opening on reperfusion and consequently less injury. More recently (PMID 27907091) we showed that ischemic preconditioning did not attenuate the elevated \[Ca2+\] at the end of 30 min ischemia or ROS production in the first 90s of reperfusion yet mPTP opening after 1 min and subsequent ROS production was attenuated. This confirms that it is something happening to mitochondria during the ischemia that determines mPTP opening and thus the extent of injury on reperfusion and HK2 binding was the only parameter that we measured that correlated with this. It is for this reason that we focussed our attention on end ischemic mitochondria. Measurements during reperfusion would be hard to interpret because during this phase mPTP opening occurs with secondary changes in many other parameters including pH, ROS and \[Ca2+\]. The fact that mt-HK2 from end-ischemic hearts can be further reduced in vitro indicates that the ischemic insult was not extreme, suggesting that further damage could have been attained to the heart. This agrees with our previous findings (PMID: 23525412) where variations to the standard ischaemic protocol led to different amounts of mt-HK2 being retained at end of ischaemia, correlating with cardiac damage at reperfusion.

5\. We appreciate the reviewer's comments on the desirability of investigating mitochondrial morphology in situ. We initiated such studies but soon recognised that the major technical and analytical challenges of such an approach were beyond the scope of the present study. However, we would point out that our TEM and light scattering studies on isolated mitochondria directly correlate with the other studies we make on isolated mitochondria and thus do have value in their own right. We must leave it to others with greater expertise to explore mitochondrial morphology in situ.

6\. With regards to Drp1, it is its translocation to mitochondria that induces fission and thus its presence in isolated mitochondria rather than the cytosol that is relevant.

We agree that working with isolated mitochondria has its pitfalls, but we are aware of those limitations and take them into account during the interpretations of our experimental data. With regards to the particular point raised by the reviewer, that conventional mitochondrial fractionation might not efficiently collect fragmented- and small mitochondria, we would note the following. 1) our TEM morphometric analysis shows that the size of our mitochondrial population spans 1-2 orders of magnitude; 2) we use a protease-based extraction in combination with differential centrifugations to collect both sub-sarcolemma and interfibrillar mitochondria; 3) the protocol we use, contrary to that used by others including the one on the reference provided by the reviewer, include a Percoll gradient to significantly reduce cellular contaminants such as endomembrane systems, broken membranes and, importantly, smaller vesicles with different buoyant densities compared to mitochondria.

7\. We agree that other fusion / fission factors could be studied but we focussed on those that had already been implicated in ischemia reperfusion injury and so might provide a possible mechanism for regulating mPTP opening via mitochondrial morphology. An extensive study of this is beyond the scope of the present study but we hope that our data may inspire others to perform more detailed studies.

8\. The reviewer suggests that an inner membrane marker might be more appropriate than VDAC. However, we are unsure why that would be the case since Mff, Drp1 etc are associated with the outer membrane which is the location of VDAC. Furthermore, permeabilisation of the outer membrane would not lead to loss of VDAC, but only of intermembrane proteins such as cytochrome c due to formation of membrane pores rather than breakage and loss of OMM fragments.

9\. Representative Western blots were shown in the supplemental material. This information was clearly stated in Fig. 1 legend but was missing in that of Fig. 5. This has been added in the updated version of the manuscript.

Reviewer\#2

General Comments

We thank the Reviewer for the positive assessment of the paper.

Specific comments

1\. We appreciate the reviewer's comment about Drp1 phosphorylation, and in retrospect this would have been a good additional measurement. Unfortunately, we no longer have the samples to perform the analysis but do now discuss this possibility in lines 727 of the revised manuscript. However, we note that for preconditioning to exert an effect via phosphorylation of Ser616, which enhances fission, it would have to cause dephosphorylation. We have previously performed extensive studies of protein phosphorylation in mitochondria isolated from control and preconditioned hearts, pre-ischemic, end ischemic and reperfused, and found no evidence of a phosphorylated protein present at the expected MWt for Drp1 (see PMID 18356542). We also feel that the literature itself is not that clear about the effects of different phosphorylations of Drp1 as we now note in our discussion.

2\. Cropped versions of Western Blot data have been added to the main figures to show representative blots. The full non-cropped membranes are shown in the supplemental material as requested by PlosOne guidelines.

Reviewer\#3

General Comments

We thank the Reviewer for their positive assessment of the paper.

Specific comments

1\. The reviewer is critical that we only use low pH and G-6-P to dissociate mtHK2 and suggest the additional use of clotrimazole and HK2 dissociating peptides. However, our previous studies have shown that the use of such peptides is open to criticism because of non-specific effects (PMID 23329796). More importantly, we showed that the mechanism of HK2 dissociation during ischemia involves the observed decrease in pH and increase in \[G-6-P\], both of which are attenuated by ischemic preconditioning. Thus, we would argue that the use of low pH and G-6-P to dissociate HK2 in isolated mitochondria is the most appropriate technique to use (please see answer to Reviewer\#1 Comment\#2 for more details).

The reviewer also points out the inhibitory effects of low pH and G-6-P on hexokinases activity. In this regard we would like to stress the following: 1) the HK2 dissociation protocol occurs prior to data acquisition and therefore, even if the inhibition and release were two possible events they do not play a role during data acquisition where conditions were identical for all treatments; 2) none of the buffers used in the present investigations contain glucose. In conclusion, when taken together with point 1, we strongly believe that hexokinase(s) activity has no effect on the interpretation of our data. These assumptions would be more difficult to prove if chemical drugs were used, because they might well induce off target effects.

2\. Cropped versions of Western Blot data have been added to the main figures to show representative blots. The full non-cropped membranes are shown in the supplemental material as requested by PlosOne guidelines.

Reviewer\#4

General Comments

We thank the Reviewer for their clear summary of our paper and their positive assessment of our data.

Specific comments

1\. We appreciate that the Reviewer regards the paper as well presented and our approach appropriate.

2\. The Reviewer is correct; HK1 is maintained when HK2 is dissociated by low pH and high \[G-6-P\] as occurs with ischemia in vivo. We have demonstrated this previously (PMID 21410437 23525412) and now make this clear on line 402-404 and by including a blot for HK1 on Fig. 1. Representative blots of experiments where mitochondria were treated with low pH ± G-6-P are now also included on Fig. 1 (full blots in the supplemental Figure S1), showing negligible effect on its release following the treatment. However, because data for this immunoblot was not collected as extensively as the others in the study, it is not possible to perform any statistical analysis regarding HK1 protein levels.

3\. Cropped versions of Western Blot data (Fig. S4) have been added to the main figures to show representative blots. The full non-cropped membranes are shown in the supplemental material as requested by PlosOne guidelines.

4\. We thank the Reviewer for highlighting our lack of clarity here and in the revised manuscript (lines 550-555, 623-627 and 665-667) we have endeavoured to explain the proposed relationships between light scattering, morphology and HK2 dissociation more clearly.

5\. We did not perform experiments investigating the effects of low pH and G-6-P on the distribution of the fission/fusion proteins. Perhaps in retrospect we should have done this but our argument was that changes in Drp1 and Dynamin 2 would only occur in the presence of cytosol from where they translocate to and from mitochondria. Since the Drp1 binds in ischemia when the pH is low and G-6-P high exposing end ischemic mitochondria to these factors would not have been expected to dissociate Drp1 and without cytosolic Drp1 additional binding would not be possible.

6\. The correlation of LS and TEM was only made for control mitochondria due to the laborious and time-consuming character of the latter technique. Initially we wished to establish whether there were any significant IMM morphology differences between control and ischemic mitochondria at baseline and this was why we looked at those two conditions first. However, and to our surprise, the lack of differences in these two major groups suggested we would be unlikely to detect significant changes with IPC. Therefore, since analysing TEM data is extremely labour intensive, we focused our efforts on LS. As noted under Point 4 above we have now endeavoured to explain our rationale more clearly.

In relation to the other comments made here by the reviewer it is unclear to us why TEM of IPC mitochondria would provide insight into the "preservation of cristae dynamics" if there was no difference detected after ischemia? The TEM snapshot at baseline shows the ultrastructure of mitochondria after isolation (which may not represent the status attained in situ) while the LS data suggests that it is the transition between different conformations that is significantly depressed. The reviewer also asks if we have results in the presence and absence (acidic pH + G6P) of HK2 during IPC. We are not sure to which data the reviewer is referring. All the data we have collected are shown in the present manuscript. If the reviewer is asking for TEM of IPC mitochondria +/- low pH plus G-6-P we do not have such data. However, as noted above we believe that the LS data we provide is more informative in providing information on subtle changes in membrane morphology and dynamics. We are unclear how either technique could provide information on the effect of HK2-dependent Drp1/ Dyn2 recruitment to mitochondria.

7\. Changes in absorbance values were calculated as the absolute value (independent of sign) of the difference between start and end; however, the axis legend was misleading. We thank the reviewer to point it out and we corrected the graphs to show "Absolute Amplitude". We also made it clear in the figure legend of Fig. 8.

Reviewer\#5

General Comments

We thank the Reviewer for their clear summary of our paper.

Specific comments

1\. We now include the Western blot of Supplementary Fig. 1into the main Figure. We appreciate the point being made about the importance of confirming the specificity of HK2 dissociation and that there are no changes in HK1 Representative blots of two separate experiments where mitochondria were treated with low pH plus G-6-P are now included on the supplemental figure S1, showing negligible effect on its release following the treatment. However, because data for HK1 was not collected routinely, it is not possible to perform any statistical analysis regarding HK1 protein levels.

2\. We checked our analysis for the data shown on Fig. 3b, specifically the comparison pointed out by the reviewer. We can confirm that there was no error reporting the statistical difference. We provide below a summary of our ANOVA table as well as the summary for the multiple comparisons so the reviewer and anyone can confirm our analysis.

Two-way RM ANOVA Matching: Across row

Assume sphericity? Yes

Alpha 0.05

Source of Variation % of total variation P value P value summary Significant?

Interaction 0.8740 0.0003 \*\*\* Yes

Perf 79.20 \<0.0001 \*\*\*\* Yes

G6P 0.3044 0.0017 \*\* Yes

Subject 18.92 \<0.0001 \*\*\*\* Yes

ANOVA table SS DF MS F (DFn, DFd) P value

Interaction 0.02233 5 0.004466 F (5, 26) = 7.021 P=0.0003

Perf 2.024 5 0.4047 F (5, 26) = 21.77 P\<0.0001

G6P 0.007777 1 0.007777 F (1, 26) = 12.23 P=0.0017

Subject 0.4833 26 0.01859 F (26, 26) = 29.22 P\<0.0001

Residual 0.01654 26 0.0006361

G6P - normal Mean 1 Mean 2 Mean Diff SE of diff N1 N2 t DF Adjusted P value

Stab 0.04603 0.04825 -0.002217 0.01456 6 6 0.1522 26.00 0.9848

Stab+CsA 0.03456 0.03706 -0.002500 0.01595 5 5 0.1567 26.00 0.9848

Isch 0.4649 0.5649 -0.1000 0.01456 6 6 6.869 26.00 \<0.0001

Isch+CsA 0.2556 0.2722 -0.01658 0.01595 5 5 1.039 26.00 0.8356

IPC 0.09800 0.1148 -0.01676 0.01595 5 5 1.051 26.00 0.8356

IPC+CsA 0.06716 0.06186 0.005300 0.01595 5 5 0.3323 26.00 0.9829

3\. We thank the Reviewer for making us aware that we had not made the link between our HK2 data and the fission protein studies sufficiently clear and we have endeavoured to address this in the revised manuscript (lines 493-496). In outline, our previous data (PMID 23525412) had shown that the extent of HK2 dissociation from mitochondria at the end of ischemia correlated well with the sensitivity of the mitochondria to mPTP opening and cytochrome c release at the end of ischemia and to the damage to the heart on reperfusion. The question we sought to address was whether HK2 was directly responsible for these effects and by displacing HK2 in vitro we showed this was not the case. Thus, the relationship between HK2 binding and mitochondrial function must be indirect. Since Drp1 had been shown to bind to heart mitochondria during ischemia and that Drp1 has effects on mitochondrial morphology which in turn is known to influence mPTP activity, it seemed appropriate to investigate whether ischemic preconditioning, which prevents HK2 dissociation, might also prevent Drp1 and Dynamin 2 binding. We recognize that the data we provide is preliminary, but it is consistent with the hypothesis that HK2 could attenuate Drp1/Dyn2 binding to mitochondria during ischemia and so prevent the detrimental effects of ischemia on mitochondrial function. We believe that our data provide the basis for future studies to test this hypothesis and thus we would like to keep the data in the paper if possible.

4\. Although we can see the point being made by the Reviewer, we would prefer to keep these data in the main body of the manuscript. We also note that none of the other 4 Reviewers asked for these data to be moved to the supplementary material.

5\. The Reviewer raises an interesting point for which we cannot give a definitive answer. However, it should be noted that both ADP and carboxyatractyloside give specific and total conversion of the ANT into the 'm' and 'c' states respectively while the effects of Ca2+ may be more complex. We can speculate that a possible explanation is that both ischemic and IPC mitochondria at end of ischemia are pre-loaded with Ca2+ and therefore do not experience its effect on LS. In fact, we previously showed (PMID 27907091) that IPC did not attenuate the elevated \[Ca2+\] at the end of 30 min ischemia. However, since we did not perform a similar quantification in the present study, we prefer to leave such speculation unless the Reviewer wishes us to include it.

10.1371/journal.pone.0234653.r003
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HEXOKINASE II DISSOCIATION ALONE CANNOT ACCOUNT FOR CHANGES IN HEART MITOCHONDRIAL FUNCTION, MORPHOLOGY AND SENSITIVITY TO PERMEABILITY TRANSITION PORE OPENING FOLLOWING ISCHEMIA

PLOS ONE

Dear Dr. Pereira,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Reviewers 1 and 3 continue to have substantial reservations regarding the manuscript.  I invite the authors to respond to their continued reservations.  Thank you very much for your interactions with the review process.  

We would appreciate receiving your revised manuscript by May 07 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Edward J. Lesnefsky, MD

Academic Editor
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Additional Editor Comments (if provided):

Reviewers 1 and 3 continue to have substantial reservations regarding the manuscript. I invite the authors to respond to their continued reservations. Thank you very much for your interactions with the review process.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

Reviewer \#3: (No Response)

Reviewer \#5: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Partly

Reviewer \#5: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#5: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#5: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#5: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: 1. Significance: The authors claimed that this study for the first time demonstrates that mtHK2 does not directly inhibit mPTP pore while previous studies show that mtHK-II provides mitochondrial protection against mPTP. However, similar findings have been obtained using a mtHK2 dissociation peptide, gene knock-down or knock-out in isolated mitochondria, in cells and in vivo as I suggested before. More specifically, it has been shown that decrease in mtHK2 itself does not induce adverse effects, suggesting that mtHK2 dissociation itself does not trigger mPTP. mtHK2 is a negative modulator but not a component of the mPTP thus it is not surprising that the lack of this negative regulator does not affect Ca -induced mPTP opening in isolated mitochondria. In addition, although there could be potential problems in the interventions used in previously studies as the authors claim, it is not proven that the intervention used in this study (G6P and low pH) is selective or more selective than other interventions. It would be interesting to examine whether the sensitivity of the mPTP to Ca is different in cardiomyocytes and other cells which expresses less or no HK2 (eg brain and hepatocytes) and if adding HK2 protein to isolated mitochondria change it.

2\. Related to point 1, what is shown here is that the dissociation does not affect Ca-induced mPTP opening, which indicates that the decrease in mtHK2 does not facilitate Ca-induced mPTP opening. This observation does not however directly address the question whether the mPTP inhibition mediated by the increase in mtHK2 is direct effect or not, a question that the authors aim to address. In addition to loss-of-function approach, gain-of-function and add-back experiments would be required to address this question.

3\. As I pointed out before, the conclusion achieved by the authors solely relies on a single intervention (G6P and low pH) in isolated mitochondria. The specificity of the intervention is not demonstrated as pointed above. Low pH has been suggested to affect the sensitivity of the mPTP and G6P, a product of HK catalytic activity, inhibits hexokinase activity. mtHK1 also negatively regulates mPTP opening and this could also be affected by G6P and low pH (even it is likely to be less extent).

The authors previously showed that the TAT-HK2 dissociation impairs vascular function in Langendorff-perfused heart, although this is controversial (PMID; 23329797). The peptide has been widely used by many researchers in wide range of fields and, nonetheless, the previous observations by the authors obtained in Langendorff heart does not necessarily indicate that the HK2 dissociation peptide (without TAT sequence) has non-specific effects in isolated cardiac mitochondria.

I agree that nothing is perfectly specific, but that's the reason why the conclusion should be supported by multiple interventions in different preparations/systems as well as by using various approaches such as gain-of-function/add-back experiments.

4\. With regards to Drp1, Drp1 translocation from cytosol to mitochondria occurs through by post-transcriptional modifications including phosphorylation thus isolated mitochondria from ischemic heart (without cytosolic Drp1) is relevant to ischemic injury but not to reperfusion induced mitochondrial fission and injury. Reperfusion activates many kinases and it is shown that reperfusion increases Drp1 at mitochondria (eg., PMID; 25332205, 24477044)

The functional and mechanistic link between HK2 and mitochondrial fission proteins including Drp1 is suggested but not demonstrated by this study, although an inverse correlation is shown. As I suggested before, it used to be believed that mitochondrial fission is deleterious and fusion is protective, but recent molecular evidence suggests that this could be incorrect (PMID 25332205 21245373, 22037195). It is critical to evaluate how the changes observed in this study functionally impact on mitochondrial function/mPTP.

Reviewer \#2: (No Response)

Reviewer \#3: The authors have not addressed my concerns adequately. Their argument not to use a HK peptide or clotrimazole is not convincing.

Reviewer \#5: Issues adequately addressed. The study has significant limitations. But these have been appropriately acknowledged.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Reviewer \#2: No

Reviewer \#3: No

Reviewer \#5: Yes: Richard N. Kitsis

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0234653.r004

Author response to Decision Letter 1

24 Apr 2020

General Comment:

We are pleased to see that Reviewers \#2 and \#5 were satisfied that in our revised manuscript we had addressed all the issues raised with our original manuscript. Reviewer \#4 did not respond but appeared to assess the first version of our paper positively. Thus, it would seem that three of the five reviewers are now happy that our paper is suitable for publication and we would not disagree with the comment of Reviewer \#5 that "The study has significant limitations. But these have been appropriately acknowledged". However, Reviewer \#1 continues to have several significant concerns and Reviewer \#3 shares one of the concerns of Reviewer \#1 that we have not satisfactorily addressed why we used glucose-6-phosphate and low pH to dissociate mitochondrial HK2 rather than a peptide or drug. However, as we argue below, we are strongly of the opinion that the use of a physiological mechanism responsible for dissociation of HK2 in ischemia is more appropriate than the use of synthetic peptides or drugs that may have potential off target effects as we will explain in detail below. We strongly believe that it would be unjustified to insist on such experiments, especially in the light of three positive reviews.

Reviewer \#1

R\#1_1. Significance: The authors claimed that this study for the first time demonstrates that mtHK2 does not directly inhibit mPTP pore while previous studies show that mtHK-II provides mitochondrial protection against mPTP. However, similar findings have been obtained using a mtHK2 dissociation peptide, gene knock-down or knock-out in isolated mitochondria, in cells and in vivo as I suggested before.

A1_1 - We understand the point that the Reviewer is making, but we respectfully disagree with their conclusions. Despite the numerous reports about hexokinase(s) on cell survival, either in the context of cardiovascular injury and/or cancer, none of these papers provide definite evidence of whether or how HK2 can modulate mPTP opening directly. These reports have certainly been important in illuminating potential upstream events leading to mt-HK2 release, including Akt activation and GSK3beta (in)activation, for example. However, they simply report mt-HK2 dissociation as the last event in a cascade that leads to mPTP opening and do not provide evidence that HK2 directly regulates mPTP opening. Indeed, a detailed search and analysis of literature reporting the keywords "hexokinase" plus "mitochondrial permeability" (or mPTP) show that the majority of works simply report an inverse correlation between the mtHK2 and cell death/mPTP without providing any mechanistic/molecular insight on how it attenuates pore opening. This is also true of our previous work. We are providing an Excel summary of these papers for the Reviewer's consideration, but we do not think that to include this level of discussion in the paper would be appropriate. However, it is in the light of this literature that we felt it was of major importance to clarify whether HK2 regulates mPTP directly, which is what we endeavour to do in the present paper in the context of the ischemic / reperfused heart. It is important to note that our present investigations do not invalidate previous reports but provide significant insights into how mt-HK2 dissociation, and any parallel/concomitant events, can enhance pore opening.

R\#1_2. More specifically, it has been shown that decrease in mtHK2 itself does not induce adverse effects, suggesting that mtHK2 dissociation itself does not trigger mPTP. mtHK2 is a negative modulator but not a component of the mPTP thus it is not surprising that the lack of this negative regulator does not affect Ca-induced mPTP opening in isolated mitochondria.

A1_2 - We fully agree with the Reviewer that mt-HK2 is not a classical negative modulator of mPTP opening in that its release does not lead to mPTP opening directly under basal conditions. However, we are addressing its role under conditions of ischemia reperfusion. It would be quite possible to envisage that ischemia induces an activated state of the mPTP that was blocked by bound HK2 and so only revealed when HK2 dissociates. This is what we address in the present paper. Furthermore, our experimental design using isolated mitochondria allows us to make important observations which would extremely difficult, if not impossible, to perform using in intact cells / in vivo:

1\) we discarded cytoplasmic and mitochondrial-unbound (extramitochondrial) factors during isolation of the organelle, suggesting that another event has to occur upon HK2 release to enhance pore opening;

2\) we isolate mitochondria either from baseline or after a damaging insult ± protective regimen, ie. if there were intramitochondrial differences that could account for increased sensitivity to pore opening upon mt-HK2 release these would still be present in our setup.

In this context, we have previously shown (PMID: 21410437, 27907091) that mitochondria isolated at end-ischaemia ± IPC show similar Ca2+ accumulation while ischaemic mitochondria show increased ROS production, which are well established mPTP triggers. The fact that complete removal of mt-HK2 does not change the sensitivity of the mPTP either in the baseline or the other tested groups, which have mitochondria with modified behaviour, suggests that mt-HK2 was not acting as "the pin of a grenade".

R\#1_3. In addition, although there could be potential problems in the interventions used in previously studies as the authors claim, it is not proven that the intervention used in this study (G6P and low pH) is selective or more selective than other interventions. It would be interesting to examine whether the sensitivity of the mPTP to Ca is different in cardiomyocytes and other cells which expresses less or no HK2 (eg brain and hepatocytes) and if adding HK2 protein to isolated mitochondria change it.

A1_3 - In relation to the first point, we respect the reviewer's position, which is similar to that of Reviewer\#3 addressed below. However, we would argue that the conditions we are using to dissociate HK2, i.e. low pH and high G-6-P, are exactly those that occur in ischemia and which we have shown previously are responsible for HK2 dissociation under those conditions. We would argue strongly that this is the most appropriate conditions to use in vitro since other interventions requiring the use of synthetic peptides or drugs are not (patho)physiological and are known to have potential off target effects. Thus, we would regard such pharmacological interventions as inferior to the protocol we use. The key point in relation to our studies is that the protocol we use is highly effective at releasing HK2 and it mimics the mechanism responsible for HK2 release in ischemia. To perform all our experiments again with a potentially non-specific chemical agent would seem to us to add little for huge effort and with the potential of confusing interpretation of the data because of off target effects. We address this further under point A1_5 below.

In relation to the second point raised by the Reviewer, we agree that these are interesting ideas, but to explore them would be outside the scope of the present study. However, using a protein abundance database (PaxDB), we were able to assess the relative quantity of HK2 in different tissues of mice (such data is not available for rats). HK2 is more abundant in heart\>muscle\>kidney\>brain\>liver. To our knowledge, there is no extensive work reporting the sensitivity to mPTP in all of the tissues mentioned above. However, it is commonly accepted among mitochondriologists that mPTP sensitivity sorts as heart\< brain\<\<liver. Although we are aware of reports showing binding of recombinant hexokinase to mitochondria (PMID: 10806396) none have evaluated mPTP sensitivity.

R\#1_4. Related to point 1, what is shown here is that the dissociation does not affect Ca-induced mPTP opening, which indicates that the decrease in mtHK2 does not facilitate Ca-induced mPTP opening. This observation does not however directly address the question whether the mPTP inhibition mediated by the increase in mtHK2 is direct effect or not, a question that the authors aim to address. In addition to loss-of-function approach, gain-of-function and add-back experiments would be required to address this question.

A1_4 - The Reviewer raises two points here. With regards to the first, we would argue that by demonstrating that removal of HK2 from preconditioned ischemic mitochondria does not increase mPTP activity to the level observed in the control ischemic mitochondria we are providing evidence that the IP-mediated inhibition of mPTP opening is not caused directly by the bound HK2. In respect of the second point, it would have been interesting to add back recombinant human HK2 to isolated mitochondria, as the reviewer suggests, but we did not have the protein available and to produce it in sufficient quantity would have been a major undertaking. Furthermore, we would not have anticipated any effect of the added HK2 since removal of the HK2 already bound was without effect. Thus, we believe our conclusions remain valid without such additional experiments.

R\#1_5. As I pointed out before, the conclusion achieved by the authors solely relies on a single intervention (G6P and low pH) in isolated mitochondria. The specificity of the intervention is not demonstrated as pointed above. Low pH has been suggested to affect the sensitivity of the mPTP and G6P, a product of HK catalytic activity, inhibits hexokinase activity. mtHK1 also negatively regulates mPTP opening and this could also be affected by G6P and low pH (even it is likely to be less extent).

A1_5 - The specificity of our approach has been discussed above at point A1_3. However, we would like to clarify some key aspects of our experimental setup because we feel that there has been some confusion among the reviewers (and potential future readers) during both revisions. We have endeavoured to clarify this in the present revision on page 18 by inclusion of a short statement and a new supplementary figure 1, that depicts our experimental design.

First, the low pH / high G-6-P conditions we employed to treat isolated mitochondria were designed to mimic the conditions experienced by the mitochondria in situ during ischemia. Our treatment induces almost total dissociation of HK2 during isolation of the organelle, but during the assay of mPTP opening and other parameters (O2 consumption, swelling, calcium-retention, inner-morphology analysis, etc.) the reaction buffers were all standard and at physiological conditions (for traditional in vitro mitochondrial studies), including pH \~7.2 and in the absence of glucose or G-6-P. Therefore, although the effects mentioned by the reviewer are true, they are mimicking those experienced by mitochondria in situ and will not be present/experienced by the mitochondria during data acquisition and thus are unlikely to affect the outcome. In contrast, the few reports in the literature which have investigated the relationship between HK2 and mPTP sensitivity perform dissociation and data acquisition in the same vessel, which could account for some discrepancies between studies.

R\#1_6. The authors previously showed that the TAT-HK2 dissociation impairs vascular function in Langendorff-perfused heart, although this is controversial (PMID; 23329797). The peptide has been widely used by many researchers in wide range of fields and, nonetheless, the previous observations by the authors obtained in Langendorff heart does not necessarily indicate that the HK2 dissociation peptide (without TAT sequence) has non-specific effects in isolated cardiac mitochondria.

A1_6 - We appreciate the Reviewer's comments but would like to stress again that we chose to employ the G-6-P + low pH protocol because it mimics the physiological situation experienced by the mitochondria during ischemia and thus does not introduced potential artefacts that might be induced by synthetic peptides or drugs. We do believe that such artefacts are potentially significant. As the reviewer rightly notes the HK2_N15 peptide (without TAT sequence) might be appropriate to use in isolated mitochondria, as its sequence does not suggest it to have a penetrating character. However, assuming it acts by competing for the HK2 binding site, it might well remain bound during mitochondrial isolation and thus exert effects in its own right. Indeed, isolated cardiac mitochondria of mice overexpressing GFP-15NG show successful dissociation of mt-HK2 and retention of the recombinant protein (Fig. 4a on PMID: 31570704). So why take the risk of using the peptide when we know that G-6P and low pH work and will not continue to exert effects after isolation of the mitochondria when G-6P is removed and pH returned to normal?

R\#1_7. I agree that nothing is perfectly specific, but that's the reason why the conclusion should be supported by multiple interventions in different preparations/systems as well as by using various approaches such as gain-of-function/add-back experiments.

A1_7 - Again, we would respectfully suggest that by using the same techniques to dissociate HK2 in isolated mitochondria as we have previously shown be responsible for the dissociation in situ during ischemia, we are employing a specific and (patho)physiological relevant protocol that is not subject to any additional effects of synthetic peptides or drugs.

R\#1_8. With regards to Drp1, Drp1 translocation from cytosol to mitochondria occurs through by post-transcriptional modifications including phosphorylation thus isolated mitochondria from ischemic heart (without cytosolic Drp1) is relevant to ischemic injury but not to reperfusion induced mitochondrial fission and injury. Reperfusion activates many kinases and it is shown that reperfusion increases Drp1 at mitochondria (eg., PMID; 25332205, 24477044)

The functional and mechanistic link between HK2 and mitochondrial fission proteins including Drp1 is suggested but not demonstrated by this study, although an inverse correlation is shown. As I suggested before, it used to be believed that mitochondrial fission is deleterious and fusion is protective, but recent molecular evidence suggests that this could be incorrect (PMID 25332205 21245373, 22037195). It is critical to evaluate how the changes observed in this study functionally impact on mitochondrial function/mPTP.

A1_8 - We totally agree with the Reviewer that the role and regulation of fusion / fission proteins in mPTP opening is complex and controversial and to fully investigate this interaction would be a massive undertaking that is far beyond the scope of our present study. We provide data that are suggestive of an involvement of Drp1 and Dnm2 which we hope may be a stimulus for further studies by others better equipped to perform them. We do not claim to have provided a full explanation of how everything fits together; nor do we think it is reasonable to be asked to do so. Indeed, the inconsistencies and controversies in the literature cited by us and the Reviewer suggest that this is likely to be far from straight forward! We do however discuss in some detail the complexities around the role and regulation of fusion / fission proteins on pages 31-32 and the limitations of our study in this regard on page 33. We hope the Reviewer will accept this is sufficient.

Reviewer\#2 (No response)

A2_1 - We assume the Reviewer is happy with our revisions.

Reviewer\#3

R\#3_1. The authors have not addressed my concerns adequately. Their argument not to use a HK peptide or clotrimazole is not convincing.

A3_1 - As noted above, we would like to stress that we chose to employ the G-6-P low pH protocol because it mimics the physiological situation experienced by the mitochondria during ischemia and thus does not introduced potential artefacts that might be induced by synthetic peptides or drugs. We do believe that such artefacts are potentially significant and unknown. We have addressed in detail the reasons why we have chosen not to use synthetic peptides under points A1_3, 5 and 6 in our response to Reviewer\#1. In the case of clotrimazole, to our knowledge all published papers showing that the drug releases HK2 from mitochondria have involved treating cells with clotrimazole rather than mitochondria and there is no evidence that it acts directly to displace HK2. Furthermore, in a drug-induced liver injury screening (PMID: 22987451) it was shown that clotrimazole significantly affects membrane potential and mitochondrial respiration (O2 consumption) in isolated liver mitochondria. An excerpt of Table 1 in PMID: 22987451 is shown below for the Reviewer inspection:

Swelling ΔΨm loss Cyto c O2 cons CII O2 cons CI

Compound Therap. class Route of admin. EC20 µM EC20 µM EC20 µM EC20 µM EC20 µM C max µM

Clotrimazole Antifungal Vaginal ND 23.9 \> 800 2.9 ND 1.02

Therefore, the utility of clotrimazole for displacing mt-HK2 will depend on the effective concentration to achieve that goal versus its off-target effects. We agree we could have explored this possibility, but since we had a (patho)physiological mimic that successfully achieved our goal, we do not believe that such studies are necessary.

Reviewer\#5

R\#5_1. Issues adequately addressed. The study has significant limitations. But these have been appropriately acknowledged.

A5_1 - We thank the Reviewer for his approval of the revised manuscript.

10.1371/journal.pone.0234653.r005
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Dear Dr. Pereira,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

The thoughtful revision and response to Reviewer 1 is appreciated. I would like the authors to consider their responses to Reviewer 1 and decide if additional portions of these responses should be incorporated into the Introduction or Discussion. I believe that the major points in the response to reviewers from the last round have been incorporated into the current revision.

==============================

We would appreciate receiving your revised manuscript by Jul 02 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>
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Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Edward J. Lesnefsky, MD

Academic Editor

PLOS ONE
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**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

Reviewer \#3: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes
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Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.
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Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors did not adequately or experimentally address any of the comments that I previously raised. I still believe that there are major flaws in this work significantly affecting its relevance and final conclusions.

Reviewer \#2: (No Response)

Reviewer \#3: My concerns are addressed, and I do not have any additional concerns.
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7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.
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**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Thank you for your positive response to our revised paper.

As requested, in this new revision, we have incorporated some of the points made in response to Reviewer\#1 in the Introduction and Discussion.

Alterations to the original manuscript are highlighted, as per your request, in a separate file.

We hope that the manuscript is now suitable for publication in the PlosOne journal and look forward to hearing your decision.
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